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Around the world, the use of protons as an alternative to photons in radiation therapy of cancer 
is becoming more widespread. The motivations for this is that protons enable a reduction of the 
radiation dose to healthy tissue or increase the dose to the tumor when compared to photons. 
However, there is currently an uncertainty related to the biological effectiveness of protons. 
Protons are known to be slightly more efficient in cell inactivation than photons, which can be 
quantified by the relative biological effectiveness (RBE), a scaling factor. In current clinical 
practice a constant RBE factor of 1.1 is applied. However, several studies including data from 
cell irradiation experiments suggest that a variable RBE factor is more appropriate. The primary 
objective of this project was to calculate and compare the dose-to-patient results of constant 
RBE versus variable RBE calculated by different models for protons. 
The calculations were done by a combination of FLUKA Monte Carlo (MC) simulations and 
post-processing using custom scripts written in Python. CT images and treatment plan 
information for a medulloblastoma patient was imported into FLUKA, where the dose and 
linear energy transfer (LET) was calculated. The RBE values were subsequently calculated for 
four different models, assuming constant tissue parameters. An in-depth investigation of the 
different model properties was performed by systematically varying the model parameters. 
RBE calculations with a simple treatment plan on a water phantom were also performed.  
The models consistently predicted an equal or lower dose in the beam-entrance region 
compared to predictions for RBE = 1.1 (RBE1.1) while greatly exceeding the predicted RBE1.1 
dose in the distal part of the planning target volume (PTV) and in the distal dose-falloff. There 
was also a considerable increase in dose distributed in the lateral direction for the PTV. The 
dose volume histograms (DVHs) revealed that structures located in close proximity to the PTV 
receive considerably higher levels of dose than predicted by RBE1.1 due to a high RBE factor, 
at times double that of the constant RBE. The RBE models also show a strong dependence on 
dose. The models appear to be largely in agreement, and the mean RBE varies about 1.4% in 
the PTV. However, the mean RBE variation increases at lower doses, such as in the esophagus 
with 6.3% variation. For a prescribed dose of 23.4 Gy to the PTV, the mean dose to the PTV 
varied between 24.9 and 25.7 for the different models, while for the lungs and esophagus the 
mean dose varied between 3.79-4.03 and 10.2-11.5, respectively.  
The results show that while the models estimations differ, they consistently deviate from the 
dose predicted using RBE of 1.1. For the investigated patient case RBE values from 1.1 to 1.4 
were seen for the target volume, while similar and higher RBE values were also observed for 
several healthy tissues, and this could be of clinical relevance. This leads to the conclusion that 
implementing a variable RBE into clinical scenarios should be considered. At least, 
practitioners should use the results provided by MC as guidance for assessing the dose until 









I would like to thank everyone who have assisted and supported me during the work with this 
master thesis. First I would like to thank my supervisors, Res. Kristian Smeland Ytre-Hauge 
and Assoc. Prof. II Sara Thørnqvist.  
Thank you, Kristian Smeland Ytre-Hauge, for presenting a variety of interesting topics and 
providing me with inspiration and the necessary tools for writing this thesis. Your guidance and 
professional commentary and input has been invaluable.  
Thank you, Sara Thörnqvist, for providing helpful and optimistic guidance, as well as reading 
through my thesis, providing insightful comments and suggestions. Also, thanks for the short 
visit to the radiology department. 
I would also like to thank Ph.D. candidates Eivind Rørvik and Lars Fredrik Fjæra, for their help, 
ideas and comments. Thank you, Eivind for reading though my thesis on several occasions, 
providing excellent feedback, both positive and negative, as well as pushing me to dig deeper 
into articles to find additional information and data. Thank you, Lars for guiding me though the 
programming-labyrinth known as DICOM and for providing me with useful up-to-date python-
scripts from your own thesis.  
Thanks to Camilla Hanquist Stokkevåg for providing the patient CT and treatment plan used in 
this thesis.  
Additionally, I would like to thank my friend and study buddy Yannick Alexander Broese van 
Groenou, for coping with me over the last two years. Your friendship, study skills and our 
internal humor and conversations has been uplifting, hilarious and vital to where and how I am 
today. If it were not for you, I might not have chosen this topic, thank you.  
Finally, a special thank you to my wonderful parents, Helge Søbstad and Sølvi Irene Bergstrøm 
Søbstad, as well as my brothers and sister. Our internal humor is legendary and is part of why 
I have been able to cope with the fatigue of studying for so long. Your support is invaluable to 
me and I am eternally grateful that you are all still with me. Asking me for help with your 
physics and math homework has been a pleasant distraction. 
 
Bergen, June 2017 










Abstract .................................................................................................................................... V 
Acknowledgements ................................................................................................................. VI 
Contents ................................................................................................................................. VII 
List of Figures and Tables ..................................................................................................... IX 
List of Abbreviations .............................................................................................................. XI 
1 Introduction ...................................................................................................................... 1 
1.1 Radiotherapy ................................................................................................................ 1 
1.2 Proton therapy.............................................................................................................. 2 
1.3 Monte Carlo simulation ............................................................................................... 4 
1.4 Project objective .......................................................................................................... 5 
2 Proton Therapy ................................................................................................................ 7 
2.1 Particle Interaction in Matter ....................................................................................... 7 
2.1.1 Multiple Coulomb scattering ................................................................................ 7 
2.1.2 Losses by ionization and excitation ..................................................................... 7 
2.1.3 Inelastic nuclear interactions ................................................................................ 9 
2.1.4 Energy to range relation ....................................................................................... 9 
2.1.5 The Bragg peak .................................................................................................. 10 
2.2 Dosimetry and Radiobiology ..................................................................................... 11 
2.2.1 Absorbed dose .................................................................................................... 11 
2.2.2 Cell killing and cell survival .............................................................................. 12 
2.2.3 Linear energy transfer ........................................................................................ 13 
2.2.4 Relative biological effectiveness ........................................................................ 14 
2.3 Treatment delivery ..................................................................................................... 15 
3 RBE models ..................................................................................................................... 17 
3.1 Wilkens model (WIL) ................................................................................................ 17 
3.2 Wedenberg model (WED) ......................................................................................... 18 
3.3 Carabe model (CAR) ................................................................................................. 20 
3.4 McNamara model (MCN) ......................................................................................... 22 
3.5 Models summary and comparison ............................................................................. 24 
4 Methods and materials ................................................................................................... 27 
4.1 Simulations with FLUKA .......................................................................................... 27 
4.1.1 Patient materials and water phantom ................................................................. 27 
4.1.2 FLUKA and Flair setup ...................................................................................... 28 
4.1.3 Running the simulation ...................................................................................... 29 
4.2 Post-processing .......................................................................................................... 29 
4.2.1 Slicer and Dose Volume Histograms ................................................................. 30 
4.2.2 2D and 1D plotting ............................................................................................. 30 
4.2.3 Uncertainty calculation ...................................................................................... 30 
VIII 
 
4.2.4 Model dependency plotting ................................................................................ 30 
5 Results ............................................................................................................................. 31 
5.1 Water phantom .......................................................................................................... 31 
5.1.1 Biological dose ................................................................................................... 31 
5.1.2 Water Phantom RBE .......................................................................................... 34 
5.2 Patient case ................................................................................................................ 36 
5.2.1 Biological dose ................................................................................................... 36 
5.2.2 Patient case RBE ................................................................................................ 39 
5.3 Uncertainties .............................................................................................................. 42 
5.4 Model dependencies .................................................................................................. 42 
6 Discussion ........................................................................................................................ 45 
6.1 Differences between the RBE models ....................................................................... 45 
6.1.1 Result dose difference ........................................................................................ 45 
6.1.2 Result RBE difference ........................................................................................ 45 
6.1.3 Model dose difference summary and comparison to other work ....................... 46 
6.2 Assumptions in normalization, RBE and uncertainties ............................................. 47 
6.3 Suggestions for further work ..................................................................................... 48 
7 Conclusion ....................................................................................................................... 49 
Bibliography ........................................................................................................................... 51 
Appendix A ............................................................................................................................. 57 
Appendix B.............................................................................................................................. 61 
Appendix C ............................................................................................................................. 65 
Appendix D ............................................................................................................................. 71 




List of Figures and Tables 
Figure 1-1: Depth dose curves for photons, protons and carbon ions ........................................ 3 
Figure 1-2: Photon vs Proton dose distribution .......................................................................... 4 
Figure 1-3: MC vs Deterministic methods ................................................................................. 6 
Figure 2-1: Multiple Coulomb Scattering .................................................................................. 8 
Figure 2-2: Lateral spreading of proton and carbon beam ......................................................... 8 
Table 2-A: Relevant variables for the Bethe-Block formula ..................................................... 9 
Figure 2-3: Absorbed dose as a function of depth ................................................................... 10 
Figure 2-4: Typical Bragg-peak and SOBP for a proton beam ................................................ 12 
Figure 2-5: Typical depth-dose curves for electron and photon beams ................................... 12 
Figure 2-6: Direct and indirect action by radiation .................................................................. 14 
Figure 2-7: RBE-LET relation ................................................................................................. 16 
Figure 2-8: Passive- and active beam shaping ......................................................................... 16 
Figure 3-1: Wilkens Alpha/Beta parameter curves .................................................................. 18 
Figure 3-2: Wilkens model RBE vs. LET ................................................................................ 19 
Table 3-A: Resulting slope for different cell lines ................................................................... 20 
Figure 3-3: Alpha parameter curves for different cell lines ..................................................... 21 
Figure 3-4: Wedenberg model RBE vs. LET ........................................................................... 21 
Figure 3-5: McNamara model RBE vs. LET ........................................................................... 23 
Table 3-B: McNamara best fit parameters ............................................................................... 23 
Table 3-C: Model summary ..................................................................................................... 24 
Table 3-D: Models RBEmax & RBEmin parameters................................................................... 26 
Figure 4-1: Geometry with patient ........................................................................................... 28 
Figure 4-2: Geometry with water phantom .............................................................................. 28 
Figure 5-1: Water phantom dose distribution model comparison ............................................ 32 
Figure 5-2: Water phantom dose distribution longitudinal plot ............................................... 33 
Figure 5-3: Water phantom dose distribution lateral plot ........................................................ 33 
Figure 5-4: Water phantom dose volume histogram ................................................................ 34 
Figure 5-5: Water phantom RBE distribution model comparison ........................................... 35 
Figure 5-6: Water phantom RBE distribution longitudinal plot .............................................. 35 
Figure 5-7: Patient [spinal] dose distribution model comparison ............................................ 37 
Figure 5-8: Patient [spinal] dose distribution longitudinal plot ............................................... 38 
Figure 5-9: Patient [spinal] dose distribution lateral plot ......................................................... 38 
Table 5-A: Patient dose coverage comparison ......................................................................... 39 
Figure 5-10: Patient dose volume histogram ............................................................................ 39 
Figure 5-11: Patient RBE distribution model comparison ....................................................... 40 
Figure 5-12: Patient RBE volume histogram ........................................................................... 41 
Table 5-B: Patient RBE coverage comparison ......................................................................... 41 
Figure 5-13: Model-𝛼/𝛽𝑥 dependence .................................................................................... 42 
X 
 
Figure 5-14: Model-LETD dependence .................................................................................... 43 
Figure 5-15: Model-dose dependence ...................................................................................... 43 
Figure A-1: Patient dose volume histogram [other structures 1] ............................................. 57 
Figure A-2: Patient dose volume histogram [other structures 2] ............................................. 57 
Figure A-3: Patient dose volume histogram [other structures 3] ............................................. 58 
Figure A-4: Patient dose volume histogram [other structures 4] ............................................. 58 
Figure A-5: Patient RBE volume histogram [Wilkens] ........................................................... 59 
Figure A-6: Patient RBE volume histogram [Wedenberg] ...................................................... 59 
Figure A-7: Patient RBE volume histogram [Carabe] ............................................................. 60 
Figure A-8: Patient RBE volume histogram [McNamara]....................................................... 60 
Figure B-1: Water phantom dose uncertainty depth plot ......................................................... 62 
Figure B-2: Water phantom RBE uncertainty depth plot ......................................................... 63 
Table C-A: Patient dose coverage comparison other structures .............................................. 65 
Table C-B: Patient RBE coverage comparison other structures .............................................. 68 
Figure D-1: Patient dose distribution [Slice 2] ......................................................................... 72 
Figure D-2: Patient dose distribution [Slice 3] ......................................................................... 73 
Figure D-3: Patient dose depth plot [Slice 2] ........................................................................... 74 
Figure D-4: Patient dose depth plot [Slice 3] ........................................................................... 74 
Figure D-5: Patient RBE distribution [Slice 2] ........................................................................ 75 
Figure D-6: Patient RBE distribution [Slice 3] ........................................................................ 76 
Figure D-7: Patient RBE depth plot [Slice 2] (wide RBE range) ............................................ 76 
Figure D-8: Patient RBE depth plot [Slice 2] (narrow RBE range) ......................................... 77 
Figure D-9: Patient RBE depth plot [Slice 3] .......................................................................... 77 
Figure E-1: Water phantom dose distribution TPS vs FLUKA comparison............................ 79 






List of Abbreviations 
CAR Carabe-Fernandez et al. model 
CPT Clinical Particle Therapy 
CSV Comma-Separated Values 
DICOM Digital Imaging and Communications in Medicine 
DSB Double-Strand Break 
DVH Dose Volume Histogram 
HUH Haukeland University Hospital 
ICRP International Commission on Radiological Protection 
ICRU International Commission on Radiation Units 
kVp Peak-Kilo Voltage 
LET Linear Energy Transfer 
LETD Linear Energy Transfer (Dose average) 
Linac Linear Accelerator 
LQ Linear Quadratic model 
MC Monte Carlo 
MCN McNamara et al. model 
MLC Multi-Leaf Collimator 
OAR Organ At Risk 
PB Pencil Beam 
PTV Planning Target Volume 
RBE Relative Biological Effectiveness 
RT Radio Therapy 
SE Standard Error 
SF Survival Fraction 
SOBP Spread-Out Bragg Peak 
TPS Treatment Planning System 
WED Wedenberg et al. model 











In 2014, over 30000 new incidences of cancer was registered in Norway (Larsen et al., 2015). 
The last few years has had a slow but steady increase in rates for all cancers combined, most 
likely due to a population increase, as well as a shift towards an older population. It is predicted 
that the occurrences will increase by 20% from 2010 to 2020 (Helse-Vest, Helse-Sør-Øst, 
Helse-Midt, Helse-Nord, & Helsedirektoratet, 2013). A clear majority (about 85-90%) of 
cancers are diagnosed among people aged 50 years and older.  
Also in 2014, roughly 11000 patients died of cancer, of which, cancers of the lung, colon, 
rectum, prostate and breast accounted for half of the mortality (Larsen et al., 2015). About half 
of all cancer patients also receive radiotherapy, and it contributes significantly as to how we 
cure many patients today (Ånensen, 2013). In 2015, about 50 Norwegian cancer patients were 
treated in other countries to receive treatment with proton therapy, due to regular radiotherapy 
being insufficient (Hartmann, 2016). 
1.1 Radiotherapy 
The dawn of radiotherapy was back in Nov 1895, when W. C. Rontgen discovered x-rays and 
its ability to excite chemicals to fluorescence. Using these invisible rays Rontgen could, using 
photographic plates placed behind what was being ‘photographed’, capture an image of the 
bony anatomy of his wife’s hand. A two months later on Jan 1896, E. H. Grubbé, a manufacturer 
of incandescent lamps and a medical student, had developed an inflammatory area on the back 
of his hand after multiple exposures every day to x-rays. After this observation, it was suggested 
that there might be other beneficial therapeutic uses of these rays (Lederman, 1981).  
Shortly after on Jan 29th, 1896, the first cancer patient was treated. This was done by placing 
an x-ray tube close to the lesion and allowing a full hour of exposure using a lead sheet to shield 
the healthy tissue surrounding the lesion; radiotherapy was born (Lederman, 1981).  
Since then, radiotherapy has undergone a wide range of technological developments, such as 
moving from the old x-ray tube and cobalt-60 machines to todays linear accelerators (linacs). 
These allows for higher energies and deeper penetration than ever before and is the standard 
for radiotherapy. Today, out of the patients with cancer receiving radiation therapy, over 86% 
are treated with photons, whereas treatment using compact linear accelerators is the dominating 
treatment technique, given to roughly 80% of the therapy patients. Other photon therapy 
techniques e.g. brachytherapy and gamma knife are given to the rest of the patients. Particle 
therapy is still a rare treatment with is received by about 0.8% of the patients (Durante & 
Paganetti, 2016).  
The term particle therapy usually refers to charged particle therapy (CPT), which involves the 
use of particles such as protons, which is the primary particle used in this thesis. Another form 
of CPT also in use and more common is electrons, but they are mostly used for shallow tumors 
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due to their light mass and consequently rapid slowdown. Hadronic therapy in general, i.e. such 
as the use of protons, also include the use of heavier ions such as helium or carbon (Jones, 
Underwood, & Dale, 2011). 
1.2 Proton therapy 
In July 1946, R. R. Wilson released an article suggesting the use of protons as a possible particle 
therapy candidate (Wilson, 1946). This was due to the depth-dose distribution of the protons 
which, unlike for photons, had an increasing effect with the depth. At the time, machines which 
could yield protons of energy 125 MeV or more were under construction which would allow 
for penetration up to 12 cm. Full penetration to any part of the body or up to 27 cm would 
require a 200 MeV beam (Wilson, 1946).   
Wilson noted that as the proton traversed through the tissue it would travel in a near-straight 
line and ionize the tissue at the cost of the its own energy. The dosage would be inversely 
proportional to the proton energy and be at its highest in the last stretch before the proton would 
come to a halt. This would mean that, unlike in conventional radiotherapy, a single field could 
deposit more dose in the target area than in the entrance area, sparing more of the healthy tissue 
(Wilson, 1946).  
The first patients were treated with protons at Lawrence Berkeley National Laboratory in 
California in 1958. Now, over 50 years later, an increasing number of particle therapy centers 
are opening or under construction all over the world. However, clinical implementation has 
been limited by the great costs of these facilities and has led to a debate over the cost over 
benefit ratio of CPT among scientists (Durante & Paganetti, 2016; McDonald & Fitzek, 2010). 
The cost however is steadily decreasing and the technology is becoming more available 
(McDonald & Fitzek, 2010).  
Most advantages associated with CPT, in this case protons, lies in the possibility to deliver the 
energy very selectively (Belli, Campa, & Ermolli, 1997). As described by Wilson, this 
possibility lies in the Bragg peak, the position at which the energy deposition is at its maximum 
(Wilson, 1946). The Bragg peak is especially important when organs at risk (OARs) are located 
directly behind the target (Belli et al., 1997). This is due to the sharp decrease in deposition of 
dose as most of the protons come to a halt. The uncertainty of this range becomes very 
important, and increases with increasing range due to range straggling (section 2.1.4). Figure 
1-1 visualizes the advantage of the Bragg peak when looking at the dose deposition for protons 
vs photons.  From a more clinical perspective figure 1-2 shows the same advantage, but during 
treatment to the brain.  
The range of the proton beam and thus the position of the Bragg peak is highly dependent on 
the initial energy. In proton therapy, multiple Bragg peaks can be used to spread out the dose 
over an area e.g. a tumor, thus creating a spread-out Bragg peak (SOBP). This is done by using 
multiple fine-tuned beam-energies in the same beam to stack the single Bragg peaks together 
(Paganetti, 2011). Applying this principle, there are two proton-beam delivery methods 
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available: Passive scattering and active scanning. Passive spreading is the first and most 
commonly used method in proton therapy as of 2006 (Schulz-Ertner et al., 2006), using 
different modulators, plates, wedges, etc. to shape the beam according to the tumor. Active 
beam scanning takes advantage of the electric charge, using magnets to bend the beam to allow 
scanning over the treatment area (Schulz-Ertner et al., 2006). These will be explained in greater 
detail in chapter 2. Independent of the method, the aim is to distribute Bragg peaks in such a 
way that the SOBP peak is covering the entire tumor.  
While the physical properties of the proton beam are well known, there are still great 
uncertainties regarding the biological effects. Unlike for photons, there are not much clinical 
data and statistics yet in terms of these effects for particle therapy. Thus, to estimate the 
treatment iso-effects of protons, one uses the biological effects of photons with a factor. This is 
in most cases expressed as the relative biological effectiveness (RBE), where the biological 
effect of protons is compared to the biological effect of x-rays, or gamma-rays such as 60Co 
radiation. The RBE is used when calculating the proton dose, which will be explained in chapter 
2. Most proton facilities assume protons to be a constant factor of 10% more effective than the 
gammas (Wilkens & Oelfke, 2004), equivalent to RBE = 1.1 (RBE1.1) as seen in the example 
in figure 1-2. This however is a simplification, as experimental evidence show that the RBE is 
not constant, but depends on variables such as the physical variables of the linear energy transfer 
(LET), i.e. the energy deposited by the passing proton per unit length, and the dose (Wilkens & 
Oelfke, 2004). This is particularly apparent for in vitro experiments, using cell cultures (Belli 
et al., 2009). However, for in vivo experiments, the observed variations in RBE is much less 
apparent and in many cases a constant RBE equal to 1.1 is clinically acceptable for most of the 
SOBP (Paganetti et al., 2002). There is however, still is a distinct increase in the RBE at the 
Figure 1-1: The depth dose curves for photons, protons and carbon ions. The protons and carbons deposit a 
large fraction of the dose deep into the medium, while the photons have a maximum dose deposition a few 
centimeters into the medium. The dashed red line shows a proton SOBP. Also notice the sharper carbon Bragg 
peak, in addition to the fragmentation tail (Ytre-Hauge, 2013). 
Figure 1-1: Depth dose curves for photons, protons and carbon ions 
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end of the proton beam range (Gueulette et al., 1997) that should be accounted for when 
planning and treating using protons in proton therapy (Paganetti et al., 2002). The effect of this 
increase will also be looked at in this project, when applying variable RBE and comparing the 
result with that of constant RBE. 
In order to calculate a variable RBE from in vitro experiments, a number of variables that reflect 
differences in radiation sensitivity as well as physical properties of the protons are normally 
used. For differences in radio-sensitivity, so called alpha- and beta values, commonly derived 
from the cell survival curve which can be read about in chapter 2, are frequently used.  Different 
models will calculate these variables differently and thus get different RBE values (Wilkens & 
Oelfke, 2004). Chapter 3 will review the models used in this project and can be read to learn 
more about these differences.  
1.3 Monte Carlo simulation 
To plan and deliver the dose correctly to the patient and tumor, a treatment planning system 
(TPS) is required. The planning system’s purpose is to plan a treatment (beams, angles, etc.) 
such that the treatment machine delivers the prescribed dose to the tumor, while sparing as 
much health tissue as possible.  
Today TPSs usually rely on pencil beam (PB) algorithms to calculate the doses, which 
compromises between accuracy and computation time (Li, 2009). Several PB algorithms have 
high uncertainties in calculations of low-dose regions, in highly heterogeneous tissues or if 
metallic materials are present. This is where Monte Carlo (MC) calculations can provide 
superior accuracy (Bauer et al., 2014; Stathakis et al., 2016; Yamashita, Akagi, Aso, Kimura, 
& Sasaki, 2012). One way to increase the accuracy of the dose calculations as well as to better 
understand the beam characteristics is to have simulations accompany the treatment planning 
system (Polster et al., 2015).  
Figure 1-2: Photon vs Proton dose distribution 
Figure 1-2: The left panel shows the dose distribution of the total dose (Gy) for the photon plan, and the right 
panel shows the RBE1.1-weighted dose distribution for the proton plans (Wedenberg, 2014). 
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The time it takes often depends of the complexity of the problem or its geometry and therefore 
deterministic methods will often be used for so-called model-problems. Model problems are 
simplified, such that it will give an approximate answer within a reasonable timespan. In reality 
on the other hand, using a deterministic method can be very time-consuming or not accurate 
enough and stochastic methods using Monte Carlo (MC) simulations can be favorable 
(Bielajew, 2013). Figure 1-3 visualizes this neatly. Stochastic sampling methods were known 
before the age of computers. The first known reference to such a method is that of Comte de 
Buffon back in 1777 (Comte de Buffon, 1777; Dunn & Shultis, 2011). Other uses of MC 
predating computes are cited by Kalos and Whitlock (Kalos & Whitlock, 2008). The modern 
MC age started when stochastic methods were applied to radiation transport calculation, in a 
documentation dated Mar. 1947 by Neumann and Richtmyer (Eckhardt, 1987).  
MC techniques, in the case of radiation therapy, is based on guided trial and error using objects 
such as particles [photons, protons, electrons, neutrons, charged nuclei, etc.] which interact with 
another object/objects in a way based on their interaction cross sections. The process, such as 
to shoot a particle at a target, is then repeated randomly by varying energies, angles, etc., until 
the results converge to their estimated values. MC attempts to model nature directly using this 
random/dynamic method, within a simple system (Bielajew, 2013).  
The FLUKA code is a general purpose MC code simulating the transport and interaction of 
different particles and is developed by the European Organization for Nuclear Research 
(CERN) and the Italian Institute for Nuclear Physics (INFN) (Böhlen et al., 2014; Ferrari, Sala, 
Fasso, & Ranft, 2005). In this thesis, the FLUKA code will be used to simulate the physical 
interactions of protons in water, as well as in human tissue. 
1.4 Project objective 
The objective of this thesis was to calculate biological doses for a clinical patient case using 
multiple RBE models for protons applied together with the FLUKA MC code, and further 
compare these results with doses from the assumption of a constant RBE of 1.1, as used in 
current clinical practice. In addition, MC simulations were also being performed on water 
phantom geometries to further investigate the properties of the different RBE models and to 
evaluate the variation in biological dose predicted by the models in a simplified setup. 




Figure 1-3: Time to solution using Monte Carlo vs. deterministic/analytic approaches. One can observe 
that while deterministic methods work in theory and modelled scenarios, when it comes to more realistic 
and complex problems, Monte Carlo methods become superior in terms of time(Bielajew, 2013). 
Figure 1-3: MC vs Deterministic methods 
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2 Proton Therapy 
This section is dedicated to the most relevant theory in regards to proton therapy. In addition, 
there will be a section at the end dedicated to treatment delivery.  
2.1 Particle Interaction in Matter 
When charged particles traverse through a material they usually interact though ionization and 
excitation of the material. Protons are called “heavy” charged particles. Particles are termed 
heavy when its rest mass is large compared to the rest mass of the electron. 
2.1.1 Multiple Coulomb scattering 
Heavy charged particles traveling through a material will not traverse in a completely straight 
line. Each particle will experience many elastic scatterings in small angles. Every interaction 
results in an energy loss and a deflection. These losses and deflections add up statistically. The 
scatterings are mostly due to each particle’s electric charge interacting with material nuclei via 
the Coulomb force. After passing through the material, the beam will have an increased lateral 
spread, which is inverse proportional to the mass of the particle and the particle velocity, and 
proportional to the charge of the particle. For a single particle, figure 2-1 visualizes the expected 
path (Henley & Garcia, 2012; Meroli, 2012).  
The number of particles absorbed in the material depends on the material thickness and density 
relative to the incident particle energy. Up to a certain thickness, it is likely that all particles 
will be transmitted, while at a sufficiently large thickness, all particles will be absorbed. This 
makes it very important to have enough particles during a MC simulation, as the number of 
particles left after a certain length can become very few and increase the uncertainty. In the case 
of radiation therapy, it is desirable that most particles are absorbed in the tumor to give the 
highest possible tumor dose. Due to the energy depositions of heavy charged particles, they will 
release the most energy as they come to a halt, as will be explained in section 2.1.2 (Henley & 
Garcia, 2012). Figure 2-2 illustrates this, together with a typical beam spread for both protons 
and carbon-ions (Ytre-Hauge, 2013).  
2.1.2 Losses by ionization and excitation 
Protons, when traveling through the patient, will lose their energy mainly through elastic 
collisions with bound electrons. When colliding, the bound electrons are then either lifted to 
higher energy levels (excitation) or completely ejected from the atom (ionization) (Henley & 
Garcia, 2012).  
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The energy loss (−𝑑𝐸) per unit length (𝑑𝑥) due to interactions with matter is called the 
stopping power and has been derived quantum mechanically by Bethe (Bethe & Ashkin, 1953). 
Relevant initial beam energies for particle therapy are typically below 220 𝑀𝑒𝑉/𝑢 for protons 
(Schardt, Elsässer, & Schulz-Ertner, 2010). In this energy range the stopping power can be 
quantified though modelling of elastic collisions with atomic electrons. The required equation 
is called the Bethe-Bloch formula. The relativistic expression is (Bethe & Ashkin, 1953; Fano, 





















Figure 2-2: Lateral spread for proton- and carbon beams as a function of depth in water. The protons have a 
three times larger broadening than the carbon ions for the highest energies depicted on the left. The dose tail, as 
a result of fragmentation of the carbon ions, can also be seen (Ytre-Hauge, 2013). 
Figure 2-2: Lateral spreading of proton and carbon beam 
Figure 2-1: Effect of Multiple Coulomb Scattering (Meroli, 2012). 
Figure 2-1: Multiple Coulomb Scattering 
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Relevant variables used in the Bethe-Block formula can be found in table 2-A. The Bethe-Bloch 
equation states that the stopping power is inversely proportional to the particle velocity and thus 
the energy loss increases as the particle comes to a halt (Bragg & Kleeman, 1904). This results 
in a distribution of dose where most is deposited towards the end of the path and is what is 
called the Bragg-peak, which is explained further in section 2.1.5.   
Symbol Definition Unit 
𝒆 Electron charge 1.6e-19 C 
𝒁𝒑 Projectile charge e 
𝒁𝒕 Target charge e 
𝒎𝒆 Electron mass 𝑀𝑒𝑉/𝑐 
𝒗 Projectile velocity 𝑚/𝑠 
𝑰 Mean excitation potential 𝑒𝑉 
𝜷 Relative particle velocity to speed of light 𝑣/𝑐 
𝑪 Shell correction  
𝜹 Density effect correction  
 
2.1.3 Inelastic nuclear interactions 
In addition to the more common excitation and ionization interactions, there are also nuclear 
interactions, which can give dose contributions in the relevant energy range used in therapeutic 
instances. Figure 2-3 shows the absorbed dose as a function of depth in a water phantom for a 
160 MeV proton beam. Nuclear interactions occur when the incoming protons interact with the 
target nucleus by knocking out other protons, neutrons or ion clusters such as alpha particles. 
These are called secondary particles and will usually have much lower energy then the incident 
particle. The secondary particles will contribute to the dose during therapy and if the secondary 
particle is neutral, such as a neutron, it will travel further, possibly depositing dose outside the 
planned target volume. Due to the directional momentum carried by the high velocity primary 
proton particles, the additional dose by these secondary particles will be deposited after the 
normal range of the primary beam (Kaderka et al., 2012).  
2.1.4 Energy to range relation 
Statistical fluctuations make it difficult to set a definitive range for each particle. The nature of 
the interactions causing energy-loss and the number of interactions required to put a particle to 
rest will vary slightly, causing statistical variations to the range. The phenomenon is called 
Table 2-A: Relevant variables for the Bethe-Block formula 
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range straggling (Gottschalk, 2012; Grupen & Shwartz, 2008). A formula applying the 








The formula integrates the stopping power from equation 2.1 above, over the entire energy 
range from the maximum energy E until full energy loss (Grupen & Shwartz, 2008).  
2.1.5 The Bragg peak 
As mentioned at the end of section 2.1.2, since the stopping power (eq. 2.1) is inversely 
proportional to the velocity of the proton, the dose deposition increases as the particle energy 
is recued. This results in a region of maximum energy loss at the end of the range, commonly 
referred to as Bragg-peak (Bragg & Kleeman, 1904; Paganetti, 2011).  
A typical Bragg-peak for protons can be seen in figure 2-4a. As explained in section 2.1.4, some 
particles traverse slightly further than the peak, due to range straggling. This effect can be 
Figure 2-3: Absorbed dose as a function of depth of a 160 MeV pristine peak in a water phantom. The 
absorbed dose is shown as percentage of the maximum absorbed dose and the individual components are 
shown as percentage of absorbed dose at that depth (Grassberger & Paganetti, 2011). 
Figure 2-3: Absorbed dose as a function of depth 
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observed in figure 2-4a where the dose doesn’t drop to zero immediately, showing the 
deposition of the leftover particles (Paganetti, 2011).  
The example in figure 2-4a displays a single beam example. In clinical situations however, the 
proton beam needs to cover an entire volume with the prescribed dose. This is done by using 
multiple beams with fine-selected energies that, when stacked together, form a plateau, as 
visualized in figure 2-4b. As mentioned in the introduction, the Bragg-peak and SOBP gives 
protons an advantage over photons and electrons (Jones et al., 2011; Paganetti, 2011). One can 
compare the percent depth-dose (PDD) of the SOBP in figure 2-4b with the typical PDD of 
electron- and photon beams shown in figure 2-5a and figure 2-5b. In short the SOBP has a great 
advantage at lower dose depositions in the entrance region and after the target region for a given 
beam angle. 
2.2 Dosimetry and Radiobiology 
2.2.1 Absorbed dose 
From the proton energy loss, the amount of ionization radiation absorbed by the medium over 
a given mass is referred to as absorbed dose, or simply dose. It is measured in Gray [Gy] which 
is defined as the absorption of 1 joule of radiation energy per kilogram of tissue. The 
International Commission on Radiation Units (ICRU) defines the absorbed dose as the mean 






where, 𝐷 being the absorbed dose, Δ𝐸 the mean energy absorbed and Δ𝑚 the mass the energy 
is absorbed by. This dose is then often modified to account for treatment delivery and biological 
effects, such as dose weighted with the relative biological effectiveness, with will be explained 
in section 2.2.4. It is important to note that the absorbed energy is not necessarily equal to the 
energy lost by the particles in the proton beam, i.e. the stopping power (section 2.1.2). This is 
because energy can be deposited outside the target volume though different secondary particles 
such as neutrons or photons (ICRU, 1998; Paganetti, 2011). 
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2.2.2 Cell killing and cell survival 
In radiation therapy the objective is to kill cancerous cells, while attempting to spare healthy 
tissue. For a proliferating cell to be considered “dead”, it must be unable to reproduce, and the 
most sensitive part of a cell is its DNA (Borges, Linden, & Wang, 2008).  
Figure 2-4: a) Graph of radiation dose with respect to depth into tissue for a proton beam (Oxford, 2015). b) 
Illustration of a typical spread-out Bragg-peak for a clinical proton beam. The beam consists of multiple 
individual beams with different specific energies in order to create an plateau of even dose distribution over 
the target volume (ICRU, 2014). 
a) b) 
Figure 2-4: Typical Bragg-peak and SOBP for a proton beam  
Figure 2-5: a) Depth-dose curves for 4-MeV, 6-MeV, 9-MeV, and 12-MeV electron beams for a 10-cm diameter 
applicator (Sam Beddar & Krishnan, 2005). b) Percent depth-dose curve of a 10 x 10 cm^2 field size 15 MV 
photon beam in a linac without the µMLC (Multi-leaf collimator) (Fischer, Todorovic, Drud, & Cremers, 
2010).  
a) b) 
Figure 2-5: Typical depth-dose curves for electron and photon beams 
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Radiation can damage the DNA molecules in two different ways, called direct- and indirect 
action. In indirect action, the particles of the beam interact with the water molecules in the cell 
causing free radicals such as hydroxyl (OH-) to be created (Hall, 2009). Free radicals are 
extremely reactive and can, following a chain of reactions, turn into hydrogen peroxide (𝐻2𝑂2). 
This can then cause molecular structural damage to the DNA strands. Due to the high amount 
of water in a cell (about 70%), a substantial damage to the DNA will be caused by the indirect 
action mechanism (Kelley, 2011). In direct action, particles from the beam or secondary 
particles ionized by the beam such as electrons, ionizes atoms in the DNA stand causing them 
to break. This type of radiation will often cause double-strand breaks, in which case, both 
strands of the DNA is damaged. Direct action becomes predominant with high ionization 
density (LET, see section 2.2.3) such as for protons. Double-strand breaks are also much harder 
for the cell to repair and thus much more like to lead to DNA aberrations which in turn can 
cause cell death (Saha, 2012). An illustration of the two interactions can be found below in 
figure 2-6. 
Cell irradiation experiments has been extensively used to quantify the cell survival as a function 
of dose. In radiotherapy the most commonly applied model is the linear-quadratic model (Lea, 
1946). The survival curve is fitted by an exponential function for cell survival fraction as a 
function of the absorbed dose: 
𝑆𝐹 = exp(−𝛼𝐷 − 𝛽𝐷2) . (2.4) 
The 𝛼 and 𝛽 values determine the shape of the curve with one linear and one quadratic 
component. These are so called single track events (one hit cell killing) and two track events 
(repairable, needs more than one hit), respectively. Different tissues will have different 𝛼/𝛽 
ratios, which characterizes their fractionation sensitivity. These ratios are very useful when 
optimizing fractionation (dose fractions) in radiotherapy, where the total dose is split into 
smaller segments (Joiner & van der Kogel, 2009). Low 𝛼/𝛽 values indicate that the tissue is 
sensitive to change in fractionation, while for high 𝛼/𝛽 ratios fractionation has a smaller effect. 
2.2.3 Linear energy transfer 
As explained in 2.2.2, direct action interactions are more likely with increasing ionization 
density, i.e. the amount of ionizations per unit length. This is referred to as the linear energy 
transfer (LET). It is the average energy imparted to the medium as the particle travels a certain 
distance, usually in keV/µm (Joiner & van der Kogel, 2009). In general, an increase of LET 
leads to a higher cell kill per dose, regardless of radiation type up to a certain point. In other 
words, the steepness of the survival fraction curve increases with increasing LET, as well as 
becoming straighter, meaning that 𝛼 increases and 𝛽 decreases (Joiner & van der Kogel, 2009). 
Protons have a higher LET at lower kinetic energies compared to photons. Thus, there are more 
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secondary particles produced, increasing the chance of double-strand breaks and cell killing 
(Joiner & van der Kogel, 2009). The concept of LETD is used then relative dose is used as a 
weighting factor to calculate the averaged LET (Guan et al., 2015). LETD is used in the RBE 
calculations.   
2.2.4 Relative biological effectiveness 
It is important when determining what kind of radiation to use, that the dose can be compared 
to that of other radiation types. This can be done using relative biological effectiveness (RBE). 
The RBE of a radiation beam being tested and biological dose [Gy(RBE)] are defined with the 
formulas: 
𝑅𝐵𝐸𝑖𝑠𝑜−𝑒𝑓𝑓𝑒𝑐𝑡 =
𝑑𝑜𝑠𝑒 𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛
𝑑𝑜𝑠𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛
 
(2.5) 
𝐵𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑑𝑜𝑠𝑒 = 𝑃ℎ𝑦𝑠𝑖𝑐𝑎𝑙 𝑑𝑜𝑠𝑒 ∗ 𝑅𝐵𝐸 (2.6) 
Figure 2-6: Direct and indirect action by radiation 
Figure 2-6: Indirect action (top of figure), the secondary electron interacts with a water molecule to produce 
a hydroxyl radical that then damages the DNA. Direct action (bottom of figure), the secondary electron 
interacts directly with the DNA. Modified from (Hall, 2009). 
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The RBE defines how much dose of the test radiation would be needed to acquire the same 
biological effect as that from a given dose of the reference radiation. The reference radiation is 
commonly 250 kVp (peak kilo voltage) X-rays or 60Co gamma-rays since these radiations are 
well known and available when RBE is to be evaluated (Joiner & van der Kogel, 2009). In 
clinical practice, proton therapy is given with the assumption of a constant RBE value of 1.1. 
The value is based on cell and animal (in vivo) experiments (Paganetti, 2015). However, several 
experimental studies show that the RBE varies depending on a variety of variables such as 
particle energy, LET and the reference radiation ratio (Wilkens & Oelfke, 2004). The RBE will 
increase as LET increases, until a maximum RBE is reached and then decrease. An example of 
this can be observed in figure 2-7. According to a study, the optimal LET for the maximum 
RBE for protons roughly 30 keV/µm (Belli et al., 1997). At the optimal LET, the RBE will vary 
depending on the survival fraction (SF in the figure). Beyond the optimal LET, the cell killing 
becomes less effected due to the phenomenon called “overkilling”. Overkilling occur when the 
radiation deposits more energy to the cell and DNA than required to kill the cell. This waste of 
energy means the process becomes less effective per unit dose (Paganetti, 2011).  
2.3 Treatment delivery 
In order to deliver the dose to the entire tumor and target volume uniformly, like a SOBP, the 
particles must be spread in lateral, axial and longitudinal directions. To do this there are two 
common delivery techniques used in particle therapy. They are called passive beam shaping 
(passive scattering) and active beam scanning (pencil beam scanning) (Schulz-Ertner et al., 
2006). Figure 2-8a shows the design of a passive beam shaping delivery system.  
Active beam shaping utilize magnets to steer the charged particles of the beam towards the 
target. The steering magnets consists of two dipoles, one for vertical and one for horizontal 
steering. Since the beam is still narrow and not scattered like in passive shaping, it is instead 
steered across the PTV, voxel by voxel and layer by layer. This can be seen in figure 2-8b 
below. The first layer is the farthermost from the beam source and is reached with the maximum 
particle energy of the beam. Once the first layer and all of its voxels has been covered, the 
particle energy is reduced to irradiate the next layer and so on (Grupen & Buvat, 2011). The 
voxels may be irradiated continuously using raster-scanning, i.e. the beam is always on, and is 
steered continuously by the dipoles. Else, the voxels may be irradiated one at a time using 
discrete spot scanning, where the beam is turned off between each voxel (Schippers, 2009).  
Compared to passive shaping the active shaping achieves higher dose conformity and thus 
sparing more of the health tissue. This is due to the passive technique shifting the SOBP towards 
the entrance region of the PTV, where normal tissue is located. In addition, due to the amount 
of material in the beam line, there will be a considerable increase in nuclear fragments. The 
lower energies of these fragments also lead to a higher LET, which in turn will lead to an 
increased dose deposited in the normal tissue in front of the PTV. However the scanning takes 
more optimization, as the SOBP is optimized separately for each voxel in the field (Schulz-




Figure 2-7: RBE-LET relation 
Figure 2-7: Dependence of relative biological effectiveness (RBE) on linear energy transfer (LET) and the 
phenomenon of overkill by very high LET radiations. The RBE has been calculated from Fig. 6.2 at cell 
surviving fraction (SF) levels of 0.8, 0.1 and 0.01 (Barendsen, 1968; Joiner & van der Kogel, 2009). 
Figure 2-8: Passive- and active beam shaping 
Figure 2-8: a) Principle of the passive dose-delivery system used for charged particle therapy. Shown is the 
incoming broadened beam. The variable range shifter has to shift the depth dose to the desired depth, whereas 
the compensator and collimator are patient-specific devices and adapt the dose distribution to the size and 
distal shape of the target volume. The lines in the body represent the distal falloff that can be shifted in depth 
with the range shifter (Schulz-Ertner, Jäkel, & Schlegel, 2006). b) Principle of the active raster scan system 
used at GSI for carbon ions. A small pencil beam is scanned in vertical and horizontal direction by using 2 
pairs of scanner magnets. By switching the energy of the synchrotron, the position of the Bragg peak can be 
chosen so that each scanned area is adapted to the extent of the target in depth (Schulz-Ertner et al., 2006). 
 a) b) 
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3 RBE models 
3.1 Wilkens model (WIL) 
Wilkens and Oelfke proposed a model for the RBE to be used in therapeutic scenarios using 
proton beams. It was made in order to study the effects of variable RBE in inverse treatment 
planning, where fast methods of calculation would be required (Wilkens & Oelfke, 2004).  
In order to acquire the RBE, equation 2. (section 2.2.4) must be written in such a way that the 
RBE will depend on dose, tissue and two different radiations: a proton beam and a reference 
radiation (Wilkens & Oelfke, 2004). Since the RBE is simply defined as the difference in doses 
needed to have the same survival of cells, it is based on the surviving fraction (SF) and the LQ 
model (Kellerer & Rossi, 1978). Though the following formula can be written in many different 
ways and thus may look slightly different depending on which article you read, the formulas 
should be equivalent (Dale & Jones, 1999; Hawkins, 1998; Joiner & Field, 1988). One way to 
write the formula, which Wilkens and Oelfke used, is: 
𝑅𝐵𝐸(𝐷𝑝, 𝛼𝑥, 𝛽𝑥, 𝛼𝑝, 𝛽𝑝) =




Here, 𝐷𝑝 is the dose of protons, while 𝛼𝑥/𝛽𝑥 (reference radiation) and 𝛼𝑝/𝛽𝑝 (proton radiation) 
are parameters used to characterize the tissue and biological system. The parameters can be 
used to draw the survival curves for the same biological system using the LQ model. 
The reason why the RBE is not constant is due to the values of 𝛼𝑝/𝛽𝑝 not being constant, since 
they depend on the LET of the proton beam. As was explained throughout section 2.1, the 
energy deposition per unit length, or LET, varies as the protons traverse through the tissue. 
Figure 3-1a shows data points from many different experiments on the survival of V79 cells (in 
vitro) with proton beams. The data is the 𝛼𝑝 parameter as a function of 𝐿𝐸𝑇𝐷 (dose averaged 
LET) up to roughly 30 keV/µm which is within the practical LET range of proton therapy. 
Looking at the low LET region, Wilkens and Oelfke assumes, with linear regression, a linear 
dependence of the 𝛼𝑝 parameter on the LETD: 
𝛼𝑝(𝐿) = 𝛼0 + 𝜆𝐿. (3.2) 
Here L is the LETD, while 𝛼0 and 𝜆 are fit parameters. When looking at the data in figure 3-1 
for the V79 cells, Wilkens and Oelfke found the best fit was obtained when 𝛼0 = 0.1 𝐺𝑦
−1 and 
𝜆 = 0.02 𝜇𝑚 𝑘𝑒𝑉−1 𝐺𝑦−1 (Wilkens & Oelfke, 2004).  
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The 𝛽𝑝 parameter, shown in figure 3-1b, is not as clear as the 𝛼𝑝 parameter. Depending on the 
study, some found an increasing 𝛽𝑝 (Belli et al., 1998), while some reported decreasing values 
(Folkard et al., 1996). Wilkens and Oelfke decided to assume a constant 𝛽𝑝, which they set 
equal to the reference radiation 𝛽𝑥, i.e.: 
𝛽𝑝(𝐿) = 𝛽𝑥. (3.3) 
As mentioned in section 2.2.4, the reference radiation when calculating RBE is often either 
200/250 kVp X-rays or cobalt 60 gamma-rays. For their model, Wilkens and Oelfke chose 
cobalt 60, which for V79 cells, means using 𝛼𝑥 = 0.112 𝐺𝑦
−1 and 𝛽𝑥 = 0.0298 𝐺𝑦
−2 (Tilly, 
Brahme, Carlsson, & Glimelius, 1999). Upon discussion, the model fits with measurements 
within experimental uncertainties, but with some limitations. The model overshoots the 
experimental values slightly when LET is above 15 keV/µm. In terms of LET it only accounts 
for primary and secondary protons. The model was also derived from the survival of V79 cells 
(in vitro) (Wilkens & Oelfke, 2004). Figure 3-2 shows the calculated RBE for different LET 
values. 
3.2 Wedenberg model (WED) 
Wedenberg, Lind and Hårdemark proposed a model for the RBE of protons, where the aim for 
the model was to “capture the basic features of the RBE using a minimum of assumptions, each 
supported by experimental data” (Wedenberg et al., 2013).  
Similar to Wilkens et. al. (section 3.1) Wedenberg et. al. observed the increase of the 𝛼 
parameter up to 30 keV/µm, after which it decreases (Belli et al., 1998). Likewise, Wedenberg 
et. al. chose to not account for this decrease, since that high LETD values are of little practical 
Figure 3-1: Wilkens Alpha/Beta parameter curves 
Figure 3-1: Data and results for the LQ parameters for the survival of V79 cells, in vitro: (a) 𝛼𝑝 versus 
LETD; (b) 𝛽𝑝 versus LETD (    (Perris, Pialoglou, Katsanos, & Sideris, 1986);    (Goodhead et al., 
1992);     (Blomquist et al., 1993);    (Belli et al., 1993); (Folkard et al., 1996);    (Wouters et al., 
1996);    (Belli et al., 1998);    (Schettino et al., 2001)). Figure by (Wilkens & Oelfke, 2004). 
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relevance compared to the energy used in clinical proton therapy (Wedenberg et al., 2013).  
Different 𝛼 parameters are reported from different studies, possibly because they use different 
cell lines. Wedenberg et. al therefore assume that the parameter is dependent on the cell type 
and propose an inverse relationship between 𝛼 and the tissue related parameter (𝛼/𝛽)𝑥. The 








Here 𝛼𝑥 is the photon parameter, L is LETD and q is a free parameter (Wedenberg et al., 2013). 
Wedenberg et. al. concluded similarly to Wilkens et. al. that the correlation between 𝛽 and LET 





The model was tested with many different cell lines including V79 cells. Depending on the 
(𝛼/𝛽)𝑥 of the cell line, the slope of the 𝛼/𝛼𝑥 vs. LETD would increase. Table 3-A lists the 








Figure 3-2: Wilkens model RBE vs. LET 
Figure 3-2: RBE values for different LET values. The experimental data for two survival levels 
(◦10%, •50%) are from (Blomquist et al., 1993), (Folkard et al., 1996), (Wouters et al., 1996) and 
(Belli et al., 1998). RBE values that were reported relative to 200 kVp (Belli et al., 1998) or 240 kVp 
X-rays (Folkard et al., 1996) were corrected to 60Co by applying a dose independent factor of 1.1 




(𝜶/𝜷)𝒙 [𝑮𝒚] (Cell line) 𝒌 [𝒌𝒆𝑽/𝝁𝒎]
−𝟏 
2.7-3.1 (V79-379A, V79-753B, DLD1)1 0.14-0.16 
7.7-7.7 (SQ20B, C1-1)2 0.057-0.057 
15-18 (C3H10T1/2, SCC25)3 0.024-0.029 
70-∞ (HCT116, M/10, HF19)4 0-0.0060 
 
Wedenberg et. al. found the free parameter q of eq. 3.4 to be 0.434 𝐺𝑦 𝜇𝑚/𝑘𝑒𝑉. This is also 
included in the k value in table 3-A and figure 3-3. Upon discussion, Wedenberg et. al. saw the 
relation between 𝛼/𝛼𝑥 and LETD that they had hypothesized. However, this was mostly from 
the low (𝛼/𝛽)𝑥 cell lines, while those with (𝛼/𝛽)𝑥 ≥ 15 showed no statistically significant 
relation. The expression (eq. 3.4) sees an increasing 𝛼/𝛼𝑥 with increasing LETD with a slope 
that decreases with increasing (𝛼/𝛽)𝑥. An advantage of the approach Wedenberg et. al used is 
that the model fits to a range of different cell lines and LETD values, instead of just a single cell 
line and radiation (Wedenberg et al., 2013). Figure 3-4 shows the calculated RBE for different 
LETD values. 
3.3 Carabe model (CAR) 
Carabe-Fernandez, Dale and Jones proposed a RBE model for high-LET via the RBEmax and 
RBEmin concepts. These represents the high and lower limits of the RBE, seen at a dose per 
fraction approaching zero and infinite respectively. The model used in this study is the 
extension by Carabe-Fernandez et al. (Carabe-Fernandez, Dale, & Jones, 2007) of the approach 
proposed by Dale and Jones (Carabe, Moteabbed, Depauw, Schuemann, & Paganetti, 2012; 
Dale & Jones, 1999; Giovannini et al., 2016).  











                                                 
1 (Baggio et al., 2002; Belli et al., 1998; Folkard et al., 1996) 
2 (Belli et al., 2000; Sgura, 2000) 
3 (Belli et al., 2000; Bettega et al., 1998) 
4 (Baggio et al., 2002; Belli et al., 2000) 





Figure 3-4: RBE as a function of LET at 2 Gy photon dose for cell lines with (𝛼/𝛽)𝑥 ratio < 4 (circles) 
and (𝛼/𝛽)𝑥 ratio ≥ 70 (squares). The experimental data is shown with filled symbols and the 
calculated data from Equation 3 has open symbols (Wedenberg, Lind, & Hardemark, 2013). 
Figure 3-4: Wedenberg model RBE vs. LET 
Figure 3-3: Experimentally obtained 𝛼/𝛼𝑥 values as a function of LET. Panel A with (𝛼/𝛽)𝑥 = 2.7–
3.1: V79-379A cells (Folkard et al., 1996), V79-753B cells (Belli et al., 1998), and DLD1 cells (Baggio 
et al., 2002). Panel B with (𝛼/𝛽)𝑥 = 7.7–7.7: SQ20B (Belli et al., 2000), and C1-1 cells (Sgura, 2000). 
Panel C with (𝛼/𝛽)𝑥 = 15–18: C3H10T1/2 (Bettega et al., 1998), and SCC25 (Belli et al., 2000). 
Panel D with (𝛼/𝛽)𝑥 ≥ 70: HCT116 (Baggio et al., 2002), M/10 cells and HF19 cells (Belli et al., 
2000). The error bars show the 95% CI. The dashed lines are obtained with Equation 2 where the 
highest and lowest (𝛼/𝛽)𝑥 in each panel is used (Wedenberg et al., 2013). 
Figure 3-3: Alpha parameter curves for different cell lines 
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Similar to Wilkens and Wedenberg, these concepts are assumed to contain the dependence of 
the RBE on LET (Giovannini et al., 2016) and are used in an expression for the RBE by 
McNamara (eq. 3.10) (McNamara et al., 2015). 
In order to assess the dependence of RBEmax and RBEmin on the LETD the authors used 4 sets 
of experimental data for V79 cells. Finding the mean, they found an (𝛼/𝛽)𝑥 value of 2.686 Gy. 
Furthermore, a reciprocal dependence was assumed, meaning that tissues with that exact 
(𝛼/𝛽)𝑥 must exactly fit the cell data, whereas other tissues must have a steeper or flatter slope 
according to their (𝛼/𝛽)𝑥 (Carabe et al., 2012). Based on this, eq. 3.6 and 3.7 could be 
expressed as: 










3.4 McNamara model (MCN) 
McNamara, Schuemann and Paganetti proposed a RBE model based on the linear quadratic 
(LQ) model and a comprehensive dataset from a review study (Paganetti, 2014). The review 
study collected 76 different reports on proton RBE with over 287 experimental data points for 
the model to fit using non-linear regression (McNamara et al., 2015).  
As mentioned in section 3.1, there are many ways to express the RBE formula, based on the 
same LQ-based RBE model. In order to have proton RBE depend on the dose average LET 





























This is the expression used in this thesis during calculation and programming. Wilkens model 
and Wedenberg model will be expressed in terms of RBEmax and RBEmin in section 3.5. The 
dependence of the RBEmax value on LETD is similarly to Carabe et. al. (Carabe et al., 2012) 
assumed to be linear. However, McNamara et. al. assume that RBEmin has a dependence on 
√(𝛼/𝛽)𝑥 (Jones, 2015): 







𝑅𝐵𝐸𝑚𝑖𝑛[(𝛼/𝛽)𝑥, 𝐿𝐸𝑇𝐷] = 𝑝2 + 𝑝3√(𝛼/𝛽)𝑥𝐿𝐸𝑇𝐷 , (3.12) 
where 𝑝0−3 are fit parameters, calculated using a non-linear regression technique in Matlab. 
Table 3-B lists the parameters while figure 3-5 shows the calculated RBE for different LET 
values.  
Table 3-B: McNamara best fit parameters 
Parameter Value Standard Error 
𝑝0 0.99064 0.014125 
𝑝1 0.35605 0.015038 
𝑝2 1.1012 0.0059972 
𝑝3 −0.0038703 0.00091303 
 
  
Figure 3-5: McNamara model RBE vs. LET 
Figure 3-5: The RBE as a function of LETD and (𝛼/𝛽)𝑥 for a dose of 2 Gy (left panel) and 8 Gy (right 
panel) as predicted by the model. The experimental data used in the fit is also plotted. The LETD is 
given relative to the reference photon radiation (McNamara, Schuemann, & Paganetti, 2015). 
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3.5 Models summary and comparison 
In table 3-C the different models are listed, with some important differences and similarities 
highlighted. 













WIL V79 30 19 Cobalt 60 
𝛼 = 0.1 + 0.02𝐿 
𝛽 = 𝛽𝑥 
𝛼𝑥 = 0.112 
𝛽𝑥 = 0.0298 
WED Many 30 24 
200 kV x-rays 



























MCN Many 20 285 Many 













An important thing to note is that some of the models uses 200-250 kV x-rays while some use 
Cobalt 60 gamma-rays as reference radiation, a more clinically relevant radiation (Mairani et 
al., 2016). This is important because the LET resulting from these photons vary, due to their 
respective secondary electrons (Mairani et al., 2016). The LET-energy relation is illustrated in 
figure 3-6. Out of the models above, Wilkens and McNamara have tried to accommodate this. 
Wilkens et al. applied a correction factor of 1.1 to all RBE values that were reported with a 
reference radiation of 200 kVp or 240 kVp X-rays (Wilkens & Oelfke, 2004). While not stated 






McNamara et al. based their study on data presented by Paganetti (Paganetti, 2014), in which 
they did not use the absolute proton LETD values, but instead used relative values to the 
reference photon generated LETD values (6MV). While not stated in the article, they implicitly 
used the following formula without the final part (Mairani et al., 2016): 
𝐿𝐸𝑇∗ ≡ 𝐿𝐸𝑇 − 𝐿𝐸𝑇𝑝ℎ (+𝐿𝐸𝑇𝑐𝑜60) (3.14) 
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As for the Wedenberg and Carabe models, they do not apply any correction factor to the LET 
for the different reference radiations. 
Another important thing is that the models of Wilkens and Carabe are based on V79 cells with 
(𝛼/𝛽)𝑥 = 3.758 and (𝛼/𝛽)𝑥 = 2.686 respectively, yet these models are to be used on different 
tissues/organs with different (𝛼/𝛽)𝑥. Carabe et al. addressed this in the article by arguing that 
the RBE-LETD relationship should include the dependence of RBE on (𝛼/𝛽)𝑥 (Carabe et al., 
2012). They assumed a simple reciprocal dependence of the RBE on (𝛼/𝛽)𝑥, with (𝛼/𝛽)𝑥 =
2.686 as the base. This is seen in the formulas 3.8 and 3.9 or in table 3-C, with the parameters 
0.843, 0.154, 1.09 and 0.006 describing the intersection point and slope of the relationship. 
Wilkens model on the other hand does not have such a correction and only uses the constant 
values of 𝛼𝑥 = 0.112 and 𝛽𝑥 = 0.0298 (Wilkens & Oelfke, 2004). Wedenberg and McNamara 
base their models on multiple cell-lines.  
The different models include different assumptions. Wilkens et. al assumes a linear dependence 
of 𝛼𝑝 on LETD and a 𝛽 that is independent of LETD (Wilkens & Oelfke, 2004). Wedenberg et. 
al. also assumes a linear 𝛼𝑝-LETD relation, but with a slope that depends on cell type 
represented by the (𝛼/𝛽)𝑥 ratio. They also see a weak correlation between 𝛽 and LETD, and 
therefore assumes 𝛽 = 𝛽𝑥 like Wilkens (Wedenberg et al., 2013). Carabe et. al. assumes a LETD 
of 10 keV µm-1 at the mid-SOBP positions for the beams they used to acquire the average 
(𝛼/𝛽)𝑥 of 2.686 Gy. They also assume a simple reciprocal dependence of RBEmin and RBEmax 
on (𝛼/𝛽)𝑥, which they assume to vary within 0.5 and 20 Gy, as well as a linear relationship 
with respect to LETD (Carabe-Fernandez et al., 2007). McNamara et. al. assumes the same 
relationship for RBEmax as Carabe, but instead assumes that RBEmin depends on √(𝛼/𝛽)𝑥.  
Figure 3-6: LET varying with photon energy 
Figure 3-6: LETD of the resulting electrons as a function of the photon energy used for normalizing 
proton LETD values (Kellerer, 2002). 
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The data points used by the different models are quite similar. Notice the figures 3-1, 3-3 and 
3-5 are actually showing the same thing. Figure 3-5 is a 3D figure with RBE, LET and (𝛼/𝛽)𝑥, 
while 3-3 shows slices of the (𝛼/𝛽)𝑥 axis, except with 𝛼/𝛼𝑝ℎ𝑜𝑡. Figure 3-1 shows a couple of 
slices together in the same plot.  
For ease of programming, all of these models needs to be expressed with the same RBE formula 
and parameters. The 𝛼𝑥 and 𝛽𝑥 parameters for the reference radiation are set to 0.112 and 
0.0298 respectively (Cobalt 60, V79 cells) for the WIL model (Wilkens & Oelfke, 2004). This 
leads to the (𝛼/𝛽)𝑥 value of ~3,7584. The other models have (𝛼/𝛽)𝑥 = 2.686 (Carabe-
Fernandez et al., 2007). The RBE expression which is used throughout this study is eq. 3.10, 
which means eq. 3.2-3.5 needs to be reformulated. Using eq. 3.6 and 3.7, the formulas are 
reformulated and are listed together with eq. 3.8, 3.9, 3.11 and 3.12 in table 3-D5.  
Table 3-D: Models RBEmax & RBEmin parameters 
Model RBEmax and RBEmin parameters 
Wilkens 
𝑅𝐵𝐸𝑚𝑎𝑥 = 0.893 + 0.179𝐿 
𝑅𝐵𝐸𝑚𝑖𝑛 = 1 
Wedenberg 
𝑅𝐵𝐸𝑚𝑎𝑥 = 1 + 0.162𝐿 
𝑅𝐵𝐸𝑚𝑖𝑛 = 1 
Carabe 
𝑅𝐵𝐸𝑚𝑎𝑥 = 0.834 + 0.154𝐿 
𝑅𝐵𝐸𝑚𝑖𝑛 = 1.09 + 0.006𝐿 
McNamara 
𝑅𝐵𝐸𝑚𝑎𝑥 = 0.991 + 0.133𝐿 
𝑅𝐵𝐸𝑚𝑖𝑛 = 1.1 − 0,007𝐿 
 
 
                                                 
5 Approximate numbers, exact numbers are used when simulating and acquiring the results. 
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4 Methods and materials 
This chapter will elaborate on the work put into the simulations, scripting and how the results 
were calculated. It is split into two parts: The TPS, FLUKA and simulations part, as well as the 
post-processing part with Python. In short, the patient CT images were converted into a voxel 
geometry and a TPS made the treatment plan. These were then imported into FLUKA which 
simulated and calculated the dose and LETD. This data was then processed in custom scripts to 
acquire the RBE. Illustrations of the patient voxel geometry and the water phantom geometry 
is found in figures 4-1 and 4-2. 
4.1 Simulations with FLUKA 
FLUKA version 2011.2c.4 was used in the thesis, as well as the advanced user interface for 
FLUKA: Flair, version 2.2-3 [R3899] (Böhlen et al., 2014; Ferrari et al., 2005).  
4.1.1 Patient materials and water phantom 
Before the CT images can be used in Flair, the dose plan for the voxel geometry is created by 
a TPS. Used in this thesis and in the PhD by Stokkevåg (Stokkevag, 2016) is the commercial 
TPS called Varian Eclipse (Varian Medical Systems, Palo Alto, CA). After importing the 
images and drawing the PTV, Eclipse attempts to deliver the prescribed dose to the PTV during 
a fast simulation, which is the basis for the beam used in Flair. The fast simulation was 
optimized by applying minimum and maximum caps on the PTV and surrounding tissue and 
running additional iterations. The water phantom used is a 20 x 20 x 20 cm3 volume of water 
with a 4 x 4 x 4 cm3 PTV in the center, assigned a prescribed biological dose of 2 Gy(RBE1.1). 
The patient data used in this thesis was provided by Stokkevåg C.H., which was used in her 
PhD (Stokkevag, 2016). It consists of CT images of a paediatric patient aged 5 and well as an 
actual treatment plan, with all target volumes and OARs delineated by experienced radiation 
oncologists. The patient is receiving treatment for medulloblastoma (brain cancer), which tend 
to spread via the cerebrospinal fluid surrounding the brain and spinal cord. The treatment 
involves 4 intensity-modulated proton therapy (IMPT) treatment fields using active scanning. 
Two of the fields are directed at the brain (shown in figure 4-1), while two are directed at the 
upper and lower spine volume, entering the patient from the back. The PTV surrounding these 









4.1.2 FLUKA and Flair setup 
Once sufficient optimization was applied to the beam, the CT images, structure plan and beam 
data were processed by a Python script made by Fjæra, L.F. (Fjæra, 2016). The script renamed 
and sorted the CT and structure files, as well as creating different files which contain settings 
and commands on how FLUKA should simulate and calculate the dose and LETD. Calibration 
curves and material conversion files were also made. Next, the CT images were corrected by 
Figure 4-1: Geometry with patient 
Figure 4-2: Geometry with water phantom 
Figure 4-1: Patient geometry of a 5-year-old girl. The spatial resolution is 0.125 x 0.125 x 0.3 cm. The blue 
object in the upper left in the range-shifter for one of the cranium fields, which is used to account for treatment-






Field 1 Field 2 
Figure 4-2: Illustration of the 20 x 20 x 20 cm3 water phantom. The PTV is located in the iso-center and is 4 x 







applying vacuum outside the patient body. This is done because in Eclipse the Hounsfield units 
(HU) outside the patient is set to -1000 (air), which is now corrected to -1024 (vacuum). To 
correct for the distance of air between patient and treatment head, a “range shifter” made of 
water was placed in each field as seen in figure 4-1. Because the water phantom is only for 
analytical purposes, the range shifter is not needed during its simulation. 
The physics settings provided by the HADROTHE card were applied. Among the different files 
there is also a beam.dat file which lists all the beam data (i.e. energy, position, angle, weighting, 
etc.). The beam.dat file was created automatically in Eclipse and is the optimized beam to 
deliver the predicted dose distribution from the TPS (4.1.1). 
The import to FLUKA was based on Fjæra’s work (Fjæra, 2016). In short, the Hounsfield Units 
(HU) were converted to density and material composition in flairs DICOM module using the 
material and calibration files. The different input cards needed were generated automatically in 
the sorting script mentioned above, though the energy spread was set manually to 0.91%. This 
value was set based to trial and error on a water phantom to get the best agreement between 
FLUKA and the TPS for the SOBP water phantom setup. 
4.1.3 Running the simulation 
For the patient, 5 independent simulation cycles were used for each of the 4 fields. 107 particles 
were assigned to each cycle, so in total the number of particles per field were 5*107 (50 million). 
The water phantom was assigned 8 cycles (1 field) with 1.25*106 particles per cycle, making a 
total of 107 (10 million) particles. Once completed the data from each cycle were merged for 
each data type (dose, LETD).  
4.2 Post-processing 
Once FLUKA had finished the simulations, the scoring files containing the dose and LETD data 
were converted back into DICOM files using a script made by Fjæra (Fjæra, 2016). The spatial 
resolution on the water phantom were 0.2 x 0.2 x 0.2 cm, while the patient files had a spatial 
resolution of 0.125 x 0.125 x 0.3 cm. The conversion was done by using the Pydicom library in 
Python, updating the dose matrix from the original DICOM files with the FLUKA calculated 
dose distribution matrix. The biological dose (RBE1.1) from FLUKA were then normalized to 
the TPS biological dose (RBE1.1). The matrixes containing the dose and LETD, which is the 
parameters needed in equation 3.10, were then used to calculate the RBE from the models. The 
(𝛼/𝛽)𝑥 parameters were assumed to be constants at 3.758 [Gy] for Wilkens model and 2.686 
[Gy] for the other models. For every voxel, an RBE value was created for each model, as well 





4.2.1 Slicer and Dose Volume Histograms 
Cumulative dose volume histograms (DVHs) visualizes how the dose is distributed in terms of 
the structure volume. 100% coverage means that the entire structure received a given amount 
of dose or more. On the other hand, 10% coverage means that only 10% of the volume received 
the given amount, or more. To draw DVHs for the patient organs and structures, an open source 
software for medical image informatics called 3D Slicer was used (client version 4.6.2, with 
SlicerRT extension version 0.18.0) (Fedorov et al., 2012). By importing the structure file made 
by the TPS and the recalculated DICOM files into Slicer, the DVHs were exported. For 
simplicity, every structure available was exported in the same file (csv format), which would 
then be interpreted by a new Python script. Once a csv file was made for every plan (RBE1.1, 
the models, etc.) the script would read all the files and ask for which files to use and which 
structures to plot.  
4.2.2 2D and 1D plotting 
To plot 2D dose plots of slices of the patient, another script made by Fjæra, L.F. was used 
(Fjæra, 2016). This script plotted the dose onto the CT images and a transverse plane was 
selected where the dose would be plotted, along with outlines of selected structures.  
Based on Fjæra’s script, a new script was created to do the 1D plotting along one of the axes. 
The script produces .dat files containing the average dose delivered to specific areas of voxels 
inside a selected plotting volume. These were then read by the same script used to plot the 
DVHs (section 4.2.1).  
4.2.3 Uncertainty calculation 
Using only the statistical uncertainty calculated by FLUKA, the relative (%) uncertainty was 
calculated for the physical dose and LETD. For each of the models, the uncertainty was 
calculated for each RBEmax and RBEmin formula before following the error propagation to find 
the uncertainty of the RBE. Details on these calculations, see appendix B.  
4.2.4 Model dependency plotting 
To plot how the different models respond to changes in certain variables, a script was made that 
could vary one of the variables in the RBE formula (3.10) while keeping the others constant. 
One variable, such as dose, was changed while the LETD and (𝛼/𝛽)𝑥 had 2 different changes 
each, making a 2x2 figure set of how the models respond to dose change. This same process 
was also done with LETD and (𝛼/𝛽)𝑥. These calculations are entirely analytical and are not 





5.1 Water phantom 
5.1.1 Biological dose 
The dose distributions from the MC simulations can be observed in figures 5-1 to 5-3. Figure 
5-1(b,d,f,h) shows the dose predicted by the models on a plane in the center of the PTV, with 
the beam entering from the left. From the RBE1.1(a) plot it is indicated that a homogeneous 
biological dose is delivered to the target. However, the results from the variable RBE models 
illustrates that this may not be the case. In general, the models predict equal or lower dose in 
the entrance region, while higher doses in the PTV and distal drop-off. The figure also include 
comparison plots (c,e,g,i) with the RBE1.1 distribution. Figure 5-2 and 5-3 shows the 
longitudinal and lateral distributions respectively. The latter two figures show that the MC 
simulations have good agreement with the TPS for calculation of RBE1.1 dose. 
Figure 5-4 is a dose volume histogram, showing the dose coverage for the different beam 
results. The models all predict a near 100% coverage of at least 1.9 Gy and less than 10% 
coverage of 2.3 Gy or more. This shows that most of the PTV, according to the models, is 





Figure 5-1: 2D water phantom dose distribution plots of the different models used in the thesis. The left column 
shows the different distributions and uses the color bar on the left. The right column shows the difference 
between the model distributions and the RBE1.1 distribution at the top (a), while using the color bar on the 
right. The PTV is a 4x4x4 cm cube in the center and the displayed 2d slices are located in the center of the 
water phantom and PTV. The dose values in the left column are transparent if the dose is less than 0.5 Gy. 





(c) WIL – RBE1.1 
(e) WED – RBE1.1 
(g) CAR – RBE1.1 




Figure 5-2: Water phantom dose distribution longitudinal plot 
 
Figure 5-3: Water phantom dose distribution lateral plot 
 
Figure 5-2: 1D longitudinal water phantom dose disribution, where depth is the x-axis equivalent in the 2D 
plot (y = ± 2). The grey box shows the boundary of the PTV on the depth-axis and is equivalent to the red box 
in the 2D plot.  
Figure 5-3: 1D lateral water phantom dose disribution, where the y-axis is the same as the y-axis in the 2D 
plot (x = ± 2). The grey box shows the boundary of the PTV on the y-axis and is equivalent to the red box in 




5.1.2 Water Phantom RBE 
Figure 5-5 shows the RBE distributions calculated by the different models. Voxels containing 
RBE values larger than 1.5 are all outside the PTV and in low dose areas. We see that the 
models predict an RBE from 1.0 to 1.15 in the entrance region and RBE from 1.15 to 1.35 in 
the PTV. The distal drop-off receives RBE values from 1.35 to above 1.5, but the dose is 
approaching 0.1 Gy which is the cutoff to transparency in the figure. Figure 5-6 is a longitudinal 
view of 5-5, with the RBE1.1 line plotted. From 5-6 we clearly see the entire PTV contains RBE 
values larger than 1.1, for any of the models. In addition, we see that the WED and MCN models 
predict RBE values around 1.1 in the entrance region. 
 
Figure 5-4: Water phantom Dose Volume Histogram (DVH). Values are ~100% from 0 to 1.7 Gy. 
Figure 5-4: Water phantom dose volume histogram 
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Figure 5-5: Water phantom RBE distribution model comparison 
Figure 5-6: Water phantom RBE distribution longitudinal plot 
Figure 5-5: 2D water phantom RBE distribution plots of the different models used in the thesis. The PTV is a 
4x4x4 cm cube in the center of a 20x20x20 cm water phantom and the displayed slices are located in the center 
of the phantom and PTV. RBE values are transparent if the dose is less than 0.1 Gy. 





























Figure 5-6: 1D longitudinal water phantom RBE distribution, where depth is the x-axis equivalent in the 2D 
plot (y = ±2). The black horizontal line is RBE1.1. The grey box shows the boundary of the PTV on the depth-
axis and is equivalent to the red box in the 2D plot. 
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5.2 Patient case 
5.2.1 Biological dose 
Figure 5-7 shows the biological doses obtained from MC simulations of the patient case. The 
PTV is encircled in red like before, while structures like the lungs (blue), heart (yellow) and 
esophagus (green) are also marked. The RBE1.1 plot (a) indicates that a homogeneous biological 
dose is delivered to the target. Like for the water phantom, figure 5-7(b,d,f,h) shows the dose 
predicted by the models on a plane at a selected location of interest (see miniature patient in 
figure), with the beam entering from the posterior (back). This plane was selected because it 
contains some structures of interest, which will be explained. The figure also include 
comparison plots (c,e,g,i) with the RBE1.1 distribution. The models seem to predict a lower dose 
in the entrance region, while a higher dose in the PTV and distal drop-off. There is also higher 
dose laterally. Figure 5-8 and 5-9 shows the longitudinal and lateral distributions respectively. 
Additional plots are found in appendix D. 
Figure 5-10 is a dose volume histogram, showing the structure-specific dose coverage for the 
different beam results in 3 different structures. Out of the available structures, these were 
selected based on relevance. The esophagus is longitudinally adjacent to the PTV, while the 
lungs are lateral. This is why figure 5-7 shows this specific location. Table 5-A contains some 
specific data points of interest from the DVH. The mean dose to the PTV were 25.3, 25.3, 24.9 
and 25.7 Gy for WIL, WED, CAR and MCN models respectively, while for the Lungs: 4.03, 
4.01, 3.79 and 3.89 Gy. The Esophagus had 11.5, 10.8, 10.4 and 10.2 Gy. Additional figures 







Figure 5-7: 2D patient dose distribution plots of the different models used in the thesis. The left column shows 
the different distributions and uses the color bar on the left. The right column shows the difference between the 
model distributions and the RBE1.1 distribution at the top, while using the color bar on the right. The PTV is 
marked by the red curve, while other organs of interest such as the lungs (blue), heart (yellow) and esophagus 
(green) are also marked. The dose values in the left column are transparent if the dose is less than 1 Gy. The 
patient arms were assumed to be “outside” the relevant volume (dose < 1 Gy) and were therefore not colored. 









(c) WIL – RBE1.1 
 
(e) WED – RBE1.1 
 
(g) CAR – RBE1.1 
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Figure 5-8: Patient [spinal] dose distribution longitudinal plot 
 
Figure 5-9: Patient [spinal] dose distribution lateral plot 
 
 
Figure 5-8: 1D longitudinal patient dose distribution, where depth is the y-axis equivalent in the 2D plot (x = 
±1). Depth = 0 cm refers to the point of entry into the patient, while approx. 12 cm is the length through the 
patient. The grey box shows the boundary of the PTV on the depth-axis and is equivalent to the red box in the 
2D plot. 
Depth 
Figure 5-9: 1D lateral patient dose distribution, where the x-axis is the same as the x-axis in the 2D plot (y = 
±1.5). This cut from -6 to 6 is all within a relevant volume in the patient geometry, with positive values towards 
the right of the patient (see miniature model). The patient is between roughly -10.5 to 10.9, however there is 
only negligible dose distributed outside this cut. The grey box shows the boundary of the PTV on the x-axis 




Table 5-A: Patient dose coverage comparison 
 TPSRBE1.1 RBE1.1 Wilkens Wedenberg Carabe McNamara 
PTV       
    D2 24.239 25.837 28.802 28.222 27.973 28.306 
    Mean 23.581 23.847 25.276 25.310 24.944 25.657 
Lungs       
    D2 20.299 19.349 23.113 22.610 22.151 22.376 
    Mean 2.3852 3.2226 4.0301 4.0075 3.7909 3.8943 
Esophagus       
    D2 16.087 17.551 25.262 23.882 23.381 22.951 
    Mean 5.6292 6.8298 11.505 10.837 10.412 10.172 
 
5.2.2 Patient case RBE 
Figure 5-11 shows the RBE distribution for the patient plan calculated by the different 
models. As also seen in the water phantom, there is an increase in RBE both longitudinally 
and laterally, with a high RBE in both esophagus and lungs. Additional slices of the patient 
are found in appendix D. 
Figure 5-10: Patient dose volume histogram 
Figure 5-10: Patient DVH for Esophagus, lungs and PTV. Specific values are shown in table 5-A. Out of all 
available structures, these were selected based on relevance. Esophagus is longitudinally adjacent to the PTV, 
while the lungs are laterally adjacent. 
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Figure 5-12 is a RBE volume histogram for PTV, lungs and esophagus, with table 5-B listing 
specific values. The esophagus seems to have RBE values from roughly 1.4 and up to 3, while 
lungs have values between 1.2 and 2.2. Both structures have much higher values than what 
the PTV contains, which is between 1.1 and 1.4. Additional figures and DVHs with other 
structures and data is found in appendix A and appendix C.  
Figure 5-11: Patient RBE distribution model comparison 
 
 
Figure 5-11: 2D patient RBE distribution plots of the different models used in the thesis. The PTV is marked 
by the red curve, while other organs of interest such as the lungs (blue), heart (yellow) and esophagus (green) 
































Figure 5-12: Patient RBE volume histogram  
 
Table 5-B: Patient RBE coverage comparison 
 Wilkens Wedenberg Carabe McNamara 
PTV     
    RBE2 1.3840 1.3000 1.2986 1.2988 
    Mean 1.1667 1.1605 1.1511 1.1840 
Lungs     
    RBE2 2.2548 2.2273 2.0248 2.0195 
    Mean 1.5662 1.5830 1.4335 1.4874 
Esophagus     
    RBE2 2.9433 2.8455 2.6268 2.4965 








The uncertainties for the physical dose of the water phantom were found to reach 1.3% in the 
distal PTV, while the RBE of the water phantom reached about 0.14%. More on the uncertainty 
is found in appendix B. 
5.4 Model dependencies 
The different models depend on dose, LETD and (𝛼/𝛽)𝑥 differently. Figures 5-13 to 5-15 
illustrates these dependencies, while varying the other two parameters.  
For the (𝛼/𝛽)𝑥 dependency we see that increasing LETD increases the effect of (𝛼/𝛽)𝑥, while 
increasing dose decreases the effect. On the other hand, while the models remain roughly 
equally dependent on (𝛼/𝛽)𝑥 with increasing LETD, we see that the WED and MCN models 
separate from the CAR model with increasing dose. Since the WIL model does not depend on 
(𝛼/𝛽)𝑥, it is a straight line. 
For the LETD dependence, we see that increasing (𝛼/𝛽)𝑥 decreases the effect of LETD, 
separating the WIL model from the others, which is unaffected. Increase the dose also seems to 
decrease the dependency, which also affects the WIL model.  
For the dose dependence, we see that increasing (𝛼/𝛽)𝑥 greatly reduces the effect of the dose 
on the WED, CAR and MCN models. On the other hand, increasing LETD will increase the 
dependence.  
Figure 5-13: Model-(𝛼/𝛽)𝑥 dependence 
  
  
Figure 5-13: Illustrates the models dependence on the tissue parameter from 0.2 to 20. LET 





Figure 5-14: Model-LETD dependence 
  
  
Figure 5-14: Illustrates the models dependence on LETD from 0.1 to 15. (𝛼/𝛽)𝑥 and dose 
are kept constant at 1,10 and 0.5,2 respectively.  
 
Figure 5-15: Model-dose dependence 
  
  
Figure 5-15: Illustrates the models dependence on the dose from 0.01 to 2. LET and 











6.1 Differences between the RBE models 
6.1.1 Result dose difference 
The dose on the water phantom gives a good first impression of the differences between the 
models and FLUKA vs the TPS (Eclipse) while working with a simple geometry and plot. Also, 
because the water phantom only contains water and all models are set up to the V79 cell line 
with (𝛼/𝛽)𝑥 = 2.686 Gy (except for the WIL model, with 3.758 Gy), the only dynamic factors 
affecting the RBE should be the LETD of the protons and physical dose. As seen in figure 5-1, 
the models in general seems to predict an equal or lower dose in the entrance region of the 
beam, while a higher dose in the SOBP/PTV and distal region. The low-dose regions excluding 
the distal drop-off, appears to have similar distributions as the RBE1.1 distribution. The MCN 
model separates itself from the others in the entrance region, where it is predicting an almost 
identical dose deposit as RBE1.1.  
For the patient plan, dose distributed past the sides of the PTV is even more noticeable for the 
models. This is caused by the increased RBE towards the distal region as seen in figure 5-11. 
The structure-specific dose coverage illustrated in figure 5-10, as well as figures A-1 to A-4 
shows that the difference between the models and RBE1.1 distribution increases with certain 
structures. Specifically, the PTV with spinal cord, brain, etc. and structures behind the PTV 
(distal region) such as the esophagus, trachea, eyes, lenses, thyroid, etc. The increased dose to 
the PTV from the models compared to the RBE1.1 distribution shows that the physical dose to 
the distal part of the target perhaps could be reduced in order to reduce the dose the OARs. 
6.1.2 Result RBE difference 
The McNamara model clearly has the narrowest RBE range in the water phantom seen in 
figures 5-5 and 5-6. Wilkens model on the other hand has the widest RBE range, which is, when 
calculated from the raw data, almost 50% wider than the McNamara model. This means that, 
when optimized against the TPS dose, the choice of model will greatly impact the resulting 
dose. 
The RBE distribution for the patient is similar to that of the water phantom in that there is a 
longitudinal and lateral increase. The structures with the largest deviation in dose from RBE1.1, 
also had the largest RBE, as further deviation from RBE1.1 would cause such differences. There 
is also a noticeable increase in difference between the models, especially the WIL model in the 
PTV and Esophagus (table 5-B).  
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6.1.3 Model dose difference summary and comparison to other 
work 
In general, the models were consistently deviating from the RBE1.1 distribution. However, as 
illustrated in the analytical figures 5-13 to 5-15 the different models react differently to change 
in the variables. As change in the (𝛼/𝛽)𝑥 ratio was not included in the calculations of the RBE, 
the primary differences in the results were caused by change in dose and LETD. However, as 
seen in the figures mentioned, the ratio makes a substantial difference in how the models behave 
and deviate from each other. 
Since the WIL model had (𝛼/𝛽)𝑥 set to 3.758 instead of 2.686 like the others (section 4.2), this 
probably caused this model to be more resistant to change in RBE at very low doses as reflected 
in figure 5-15. However, the WIL model is also the model that depends the most on LETD in 
its RBEmax formula (table 3-D). Therefore, while RBEmax is lower at low LETD, it increases 
faster than the other models with increasing LETD. This is likely what caused the WIL model 
to predict the widest dose- coverage for the PTV as visualized in figure 5-10 and table 5-A. 
The WED model predicted typically an RBE in-between the values estimated by the other 
models. This could be because the model is less dependent on LETD than WIL model, due to a 
different tissue parameter. Arguably, the model is also less dependent on LETD than the CAR 
and MCN models for high fraction doses, since the others have an RBEmin-LETD dependence. 
The WED model is also the model with the highest initial RBEmax at low LETD. Looking at 
tissue dependence, the model, along with the MCN model, is the least dependent on (𝛼/𝛽)𝑥 
even at lower doses and LETD (ignoring Wilkens). This is could be due to the non-dependent 
RBEmin.  
The Carabe model is the only model where RBEmin is increasing away from 1 as LETD 
increases. This effect becomes more important with increasing dose and LETD, as seen from 
formula 3.10 and figure 5-14, where the model starts to separate itself from the other models. 
The model seems to be susceptible to larger LETD changes compared to the other models. The 
CAR model has, like the WED model, predicted doses and RBE that often was in-between the 
other models. 
The least variation-susceptible model appears to be the McNamara model. The model had in 
general the narrowest RBE range both for the water phantom and for the patient. This is 
probably due to the model having the lowest RBEmax-LETD dependence, as well as an RBEmin 
approximately 1 (within a relevant LETD range). As mentioned above, the model is also one of 
the least dependent on the tissue parameter, probably due to the square root in the RBEmin 
formula.  
In a comparison article by Giovannini et al. they found some similar dose distribution results 
when they compared different models such as the WED and CAR models to the RBE1.1 
distribution. Their analytical plots, where they look at the RBE-LET dependence and RBE-dose 
dependence, show similar trends to that of figure 5-14 and 5-15. They also make a great point 
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that using opposite beam arrangements, if available, could be preferable to reduce the LETD 
and RBE values in structures (Giovannini et al., 2016). McNamara et al. also compared their 
model with the WED and CAR model in terms of RBE-dose, RBE-LET and RBE-(𝛼/𝛽)𝑥 
dependencies and found similar results (McNamara et al., 2015). Polster et al. found that the 
WED model calculated the lowest RBE in their water phantom, with the WIL and CAR models 
predicting higher RBE. This is clearly different than what we see in figure 5-6. However, when 
comparing the WED model to the RBE1.1 on a patient they saw a similar distribution difference 
(Polster et al., 2015). 
6.2 Assumptions in normalization, RBE and 
uncertainties 
One of the most important factors to acquire adequately correct data was the normalization 
between FLUKA and the TPS. It was done by finding the median dose of the TPS in the PTV 
[brain] or PTV [spine] depending on the field and setting this value as the median dose for the 
FLUKA field in the same region. However, this method can lead to large uncertainties. Without 
knowing the number of particles used in the treatment or the conversion factor between the 
monitor unit output and the number of particles the normalization can’t be completely accurate. 
For the purposes of this thesis, the normalization method was assumed to be accurate enough 
for the comparison between the models. The resulting doses found in this thesis should not be 
used in any clinical scenario, as the normalization must be done properly. FLUKA-TPS 
comparison figures are found in appendix E. 
The (𝛼/𝛽)𝑥 ratios were assumed as constants, which in general is not the case. This is not an 
issue for the water phantom case (as there is no cells in the water), but for the patient case it 
might lead to significantly incorrect RBE and thus incorrect dose in certain regions and 
structures. Including variable tissue parameters would also lead to increased uncertainty, since 
the (𝛼/𝛽)𝑥 uncertainty would be considered in formula B. 1. The WIL model was the only 
model where (𝛼/𝛽)𝑥 = 3.758 Gy was used, due to equations 3.2 and 3.3 not allowing for other 
tissue parameters. This, of course, would lead to some noticeable differences compared to the 
other models as discussed in section 6.1.3. 
Only the statistical uncertainty calculated by FLUKA were considered in the uncertainty 
calculations of the water phantom in this thesis. Fjæra (Fjæra, 2016) touches on the uncertainties 
of some of the pre-simulation processes. With this in mind, figure B-1 shows that the 
uncertainty of the physical dose is low, so that we most likely have used enough particles in the 





6.3 Suggestions for further work 
This thesis did not look at the models dependence on a variable (𝛼/𝛽)𝑥 as part of the patient 
dose and RBE results. Further work should be put into creating a way to implement tissue 
parameters as structure matrixes which for example can be used alongside the structure 
DICOM-file exported by the TPS. Implementing this into the RBE calculation should improve 
results and allow for more organ specific research. It could however, increase the uncertainties 
related to RBE and model doses (Gy(RBE)). 
More work should be done on quantifying the uncertainty of dose and RBE on patient data, 
especially when more than one beam is included. The implementation of the normalization 
would probably contain some difficult decisions as to how a low dose high uncertainty voxel 
from one field would combine with a high dose low uncertainty voxel from another.  
There should be more work put into generating experimental data on the effects of proton 
therapy. Right now, this data is scarce compared to that of photon therapy and could greatly 
increase our understanding of variable RBE, leading to more accurate models in the future. 




The models used in this thesis applies various assumptions regarding the different RBE 
relationships, but do give consistent deviations from the current clinical practice of assuming a 
constant RBE of 1.1. There has been observed a general trend where the models predict lower 
dose- and RBE values in the entrance region, while predicting higher values in the PTV and 
distal drop-off. In addition, there has been observed a lateral dose and RBE increase, which was 
particularly apparent in the patient case. These longitudinal and lateral increases could be of 
clinical importance in regards to certain OARs.  
RBE values up to 1.38 (RBE2) was observed in the target volume, while elevated biological 
dose was seen for all structures, especially for structures in low-dose regions, which had RBE 
values up to 8.1 (RBE2) (appendix C). The RBE98 was observed to always be greater or equal 
to 1.1 in any structure, regardless of model, with the exceptions of the body, bladder and normal 
tissue, which either had parts of the structure in front of the PTV (entrance region) or received 
a very low dose (mean ≤ 0.1 Gy).  
The results suggest that implementing variable RBE calculations into clinical scenarios should 
be considered, at least with dependence on dose and LETD, and possibly variable tissue 
parameters when this is implemented into the calculation. This is especially the case if there are 
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DVHs and RBE-VHs for the other structures than shown in figures 5-10 and 5-12. Structures 
Uterus/Cervix and Vertebrae were not included due to very low doses (D2 < 0.5 Gy) and poor 
resolution. 
Figure A-1: Patient dose volume histogram [other structures 1] 
 
Figure A-2: Patient dose volume histogram [other structures 2] 
 
Figure A-1: DVH with additional structures. Specific data found in Appendix C. 







Figure A-3: Patient dose volume histogram [other structures 3] 
Figure A-3: DVH with additional structures. Specific data found in Appendix C. 
Figure A-4: Patient dose volume histogram [other structures 4] 
Figure A-4: DVH with additional structures. Specific data found in Appendix C. 
59 
 
Figure A-5: Patient RBE volume histogram [Wilkens] 
 





Figure A-5: RBE Volume Histogram for Wilkens model only, with all structures. Specific data found in 
Appendix C. 




Figure A-7: Patient RBE volume histogram [Carabe] 
 
Figure A-8: Patient RBE volume histogram [McNamara] 
 
  
Figure A-8: RBE Volume Histogram for McNamara model only, with all structures. Specific data found in 
Appendix C. 





Sub-formulas used to calculate the uncertainty of the RBE and how they are derived. B.1 is 
the uncertainty of the RBE formula 3.10. Using B.2, formulas B.3-B.5 are derived. Figures B-
1 and B-2 shows the relative uncertainty calculated for the physical dose and the RBE for the 
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2 𝐷2 (𝐵. 2) 
𝜕𝑅𝐵𝐸
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Figure B-1: Water phantom dose uncertainty depth plot 
Figure B-1: 1D uncertainty plot for the physical dose of the water phantom. The grey box shows the boundary 
of the PTV on the depth-axis.  
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Figure B-2: 1D uncertainty plot for the RBE of the water phantom. The grey box shows the boundary of the 







Data from the figures in Appendix A. Table C-A lists the dose at a specific volume amount [%] 
as well as the mean dose in a structure. Table C-B lists RBE. 
Table C-A: Patient dose coverage comparison other structures 
 TPS FLUKA WIL WED CAR MCN 
Body       
    D98 0.0033 0.0048 0.0056 0.0056 0.0054 0.0055 
    D80 0.0330 0.0484 0.0562 0.0566 0.0542 0.0550 
    D50 0.0825 0.2431 0.3226 0.3317 0.2925 0.3005 
    D2 24.031 25.035 27.193 26.922 26.634 27.150 
    Mean 6.2154 6.5599 7.1552 7.1690 6.9890 7.2038 
Bladder       
    D98 0.0020 0.0023 0.0026 0.0026 0.0026 0.0026 
    D80 0.0202 0.0235 0.0267 0.0266 0.0260 0.0261 
    D50 0.0506 0.0589 0.0667 0.0667 0.0651 0.0652 
    D2 0.0993 0.4964 0.8806 0.8793 0.7950 0.8070 
    Mean 0.0042 0.0569 0.1042 0.1038 0.0936 0.0945 
Brain       
    D98 23.146 22.728 23.356 23.648 23.236 24.123 
    D80 23.501 23.399 24.022 24.275 23.886 24.753 
    D50 23.746 23.905 24.710 24.897 24.535 25.364 
    D2 24.219 25.741 27.968 27.714 27.449 27.976 
    Mean 23.723 24.012 24.972 25.114 24.758 25.554 
Colon       
    D98 0.0022 0.0066 0.0084 0.0084 0.0081 0.0082 
    D80 0.0225 0.0660 0.0849 0.0848 0.0818 0.0820 
    D50 0.0564 0.1966 0.2744 0.2816 0.2491 0.2605 
    D2 1.6549 3.4698 4.9647 4.9669 4.5253 4.6724 
    Mean 0.1063 0.4335 0.6423 0.6480 0.5841 0.6050 
Esophagus       
    D98 0.1324 0.1617 0.3726 0.3700 0.3356 0.3323 
    D80 1.1724 1.2298 2.8440 2.7251 2.5151 2.4527 
    D50 4.7533 6.1931 11.676 10.977 10.424 10.170 
    D2 16.087 17.551 25.262 23.882 23.381 22.951 
    Mean 5.6292 6.8298 11.505 10.837 10.412 10.172 
Eyes       
    D98 0.5481 1.9828 2.5807 2.6406 2.3735 2.5166 
    D80 2.5130 4.5775 5.8147 5.8783 5.3912 5.6371 
    D50 7.4210 9.3741 11.087 11.141 10.490 10.905 
    D2 20.746 20.355 21.723 21.792 21.291 21.985 
    Mean 8.6135 9.9618 11.440 11.493 10.931 11.346 
 
 




    D98 0.0024 0.0027 0.0030 0.0030 0.0029 0.0029 
    D80 0.0244 0.0278 0.0303 0.0302 0.0298 0.0297 
    D50 0.0611 0.0695 0.0758 0.0755 0.0746 0.0743 
    D2 8.3848 9.4817 14.450 13.840 13.182 13.117 
    Mean 0.5570 0.7417 1.2461 1.2000 1.1278 1.1196 
Kidneys       
    D98 0.0056 0.3262 0.4164 0.4460 0.3704 0.3952 
    D80 0.0560 0.6800 0.9199 0.9473 0.8472 0.8880 
    D50 0.7360 2.6946 3.5666 3.6245 3.2745 3.4402 
    D2 20.821 19.310 22.304 21.998 21.478 21.880 
    Mean 3.8563 5.0576 6.2234 6.2153 5.8554 6.0474 
Lenses       
    D98 1.4544 3.2715 4.2430 4.2930 3.8930 4.0930 
    D80 2.0174 4.2420 5.4420 5.4810 5.0420 5.2577 
    D50 2.7764 5.3900 6.8500 6.8818 6.3333 6.6300 
    D2 4.7651 7.8280 10.128 10.028 9.4280 9.7280 
    Mean 2.8861 5.4161 6.8718 6.9073 6.3852 6.6467 
Liver       
    D98 0.0022 0.0030 0.0035 0.0034 0.0034 0.0034 
    D80 0.0222 0.0309 0.0350 0.0349 0.0342 0.0342 
    D50 0.0556 0.0774 0.0875 0.0873 0.0856 0.0856 
    D2 8.2988 9.7575 13.701 13.315 12.659 12.767 
    Mean 0.4464 0.6448 0.9475 0.9277 0.8706 0.8793 
Lungs       
    D98 0.0033 0.0647 0.1172 0.1183 0.1109 0.1130 
    D80 0.0330 0.2384 0.3691 0.3756 0.3351 0.3490 
    D50 0.0825 0.6529 0.9394 0.9583 0.8569 0.8884 
    D2 20.299 19.349 23.113 22.610 22.151 22.376 
    Mean 2.3852 3.2226 4.0301 4.0075 3.7909 3.8943 
Normal Tissue       
    D98 0.0236 0.0375 0.0526 0.0520 0.0499 0.0493 
    D80 0.6663 1.9310 2.8209 2.8512 2.5762 2.6781 
    D50 5.2403 7.0219 8.9303 8.9513 8.3442 8.6537 
    D2 20.615 20.208 21.742 21.505 20.995 21.594 
    Mean 7.2695 8.1549 9.5316 9.5658 9.0878 9.4206 
PTVbrain       
    D98 21.929 21.936 23.298 23.519 23.106 23.889 
    D80 23.417 23.340 24.041 24.278 23.888 24.741 
    D50 23.715 23.881 24.797 24.956 24.593 25.399 
    D2 24.213 25.780 28.338 27.988 27.716 28.179 









    D98 21.231 19.530 22.533 22.507 21.875 22.469 
    D80 23.211 22.334 24.947 24.906 24.364 25.007 
    D50 23.581 23.601 26.219 26.005 25.571 26.111 
    D2 24.400 26.056 29.853 28.864 28.740 28.759 
    Mean 23.461 23.425 26.192 25.927 25.518 26.007 
PTV       
    D98 21.755 21.016 23.185 23.326 22.842 23.486 
    D80 23.379 23.237 24.098 24.317 23.919 24.757 
    D50 23.696 23.851 24.995 25.110 24.733 25.507 
    D2 24.239 25.837 28.802 28.222 27.973 28.306 
    Mean 23.581 23.847 25.276 25.310 24.944 25.657 
Spinal Cord       
    D98 22.984 23.178 24.777 24.946 24.282 25.153 
    D80 23.368 23.944 25.452 25.541 25.051 25.840 
    D50 23.650 24.700 26.285 26.234 25.978 26.611 
    D2 24.240 26.455 28.591 28.246 28.232 28.622 
    Mean 23.641 24.725 26.338 26.303 25.997 26.659 
Stomach       
    D98 0.0023 0.0050 0.0059 0.0058 0.0057 0.0057 
    D80 0.0235 0.0501 0.0591 0.0589 0.0577 0.0576 
    D50 0.0587 0.1890 0.3090 0.3117 0.2758 0.2837 
    D2 7.9692 9.8179 13.705 13.320 12.651 12.761 
    Mean 0.4858 0.9318 1.4088 1.3847 1.2872 1.3034 
Thyroid       
    D98 0.0066 0.1873 0.3522 0.3572 0.3286 0.3357 
    D80 0.0664 0.4410 0.6536 0.6628 0.5951 0.6204 
    D50 0.2889 0.8546 1.2658 1.2788 1.1426 1.1925 
    D2 11.934 13.206 19.417 18.414 17.836 17.637 
    Mean 1.5857 2.2512 3.6821 3.5433 3.3333 3.3155 
Trachea       
    D98 0.1063 0.6641 1.1772 1.1756 1.0706 1.1027 
    D80 0.4561 1.3210 2.7116 2.6314 2.4130 2.3779 
    D50 4.5169 6.4673 12.472 11.570 11.050 10.690 
    D2 20.955 19.291 27.398 25.628 25.419 24.676 
    Mean 7.1100 7.8296 12.736 11.941 11.593 11.278 
 
Structures Uterus/Cervix and Vertebrae were not included due to very low doses (D2 < 0.5 Gy) 




Table C-B: Patient RBE coverage comparison other structures 
 WIL WED CAR MCN 
Body     
    RBE98 0.3950 0.3912 0.3517 0.3480 
    RBE80 1.1809 1.1949 1.1508 1.1856 
    RBE50 1.4504 1.4858 1.3322 1.3981 
    RBE2 5.6736 5.2996 4.9577 4.5026 
    Mean 1.7755 1.7568 1.6189 1.6209 
Bladder     
    RBE98 0.4475 0.4408 0.3967 0.3876 
    RBE80 1.6461 1.6587 1.4968 1.5199 
    RBE50 2.1177 2.0871 1.8911 1.8776 
    RBE2 7.5408 6.9854 6.5692 5.8730 
    Mean 2.5905 2.4965 2.2925 2.1905 
Brain     
    RBE98 1.1037 1.1040 1.1038 1.1040 
    RBE80 1.1398 1.1400 1.1398 1.1400 
    RBE50 1.1999 1.2000 1.1999 1.2000 
    RBE2 1.2960 1.2960 1.2960 1.2960 
    Mean 1.1436 1.1502 1.1339 1.1704 
Colon     
    RBE98 1.2128 1.3081 1.1145 1.1778 
    RBE80 1.4602 1.5134 1.3409 1.4037 
    RBE50 1.6904 1.7154 1.5375 1.6001 
    RBE2 6.0937 5.6892 5.3209 4.8348 
    Mean 2.0828 2.0639 1.8672 1.8674 
Esophagus     
    RBE98 1.5127 1.3705 1.3398 1.3315 
    RBE80 1.7441 1.6427 1.5838 1.5586 
    RBE50 2.0752 1.9719 1.8565 1.8188 
    RBE2 2.9433 2.8455 2.6268 2.4965 
    Mean 2.1214 2.0165 1.8988 1.8542 
Eyes     
    RBE98 1.1078 1.1082 1.1050 1.1066 
    RBE80 1.1781 1.1825 1.1501 1.1665 
    RBE50 1.2953 1.3065 1.2252 1.2664 
    RBE2 1.6058 1.6204 1.4804 1.4912 
    Mean 1.3087 1.3177 1.2365 1.2873 
Heart     
    RBE98 1.5007 1.4543 1.3554 1.3655 
    RBE80 2.1260 2.0849 1.9016 1.8878 
    RBE50 2.8807 2.7930 2.5574 2.4650 
    RBE2 8.1046 7.5219 7.0678 6.3476 
    Mean 3.3540 3.2079 2.9625 2.8064 
 
 




    RBE98 1.1213 1.1247 1.1085 1.1164 
    RBE80 1.3047 1.3158 1.1859 1.2646 
    RBE50 1.4190 1.4386 1.3147 1.3824 
    RBE2 1.8008 1.8017 1.6463 1.6751 
    Mean 1.4307 1.4491 1.3228 1.3826 
Lenses     
    RBE98 1.3030 1.3040 1.1084 1.1857 
    RBE80 1.3395 1.3404 1.1848 1.3321 
    RBE50 1.4005 1.4010 1.3107 1.3951 
    RBE2 1.4980 1.4980 1.4924 1.4958 
    Mean 1.4012 1.4102 1.3002 1.3549 
Liver     
    RBE98 1.3238 1.3336 1.1894 1.3039 
    RBE80 1.6567 1.6751 1.5019 1.5633 
    RBE50 2.4769 2.4185 2.2057 2.1568 
    RBE2 7.8151 7.2603 6.8139 6.1228 
    Mean 2.9746 2.8692 2.6369 2.5276 
Lungs     
    RBE98 1.1348 1.1386 1.1133 1.1251 
    RBE80 1.3498 1.3657 1.2336 1.3191 
    RBE50 1.5282 1.5592 1.3992 1.4590 
    RBE2 2.2548 2.2273 2.0248 2.0195 
    Mean 1.5662 1.5830 1.4335 1.4874 
Normal Tissue     
    RBE98 0.9268 1.0051 0.9194 1.1086 
    RBE80 1.1374 1.1881 1.0943 1.1866 
    RBE50 1.3729 1.3798 1.2772 1.3307 
    RBE2 3.4501 3.3019 3.0492 2.8896 
    Mean 1.5733 1.5638 1.4558 1.4848 
PTVbrain     
    RBE98 1.1038 1.1040 1.1038 1.1040 
    RBE80 1.1399 1.1400 1.1398 1.1400 
    RBE50 1.2001 1.2000 1.1999 1.2000 
    RBE2 1.2964 1.2960 1.2960 1.2960 
    Mean 1.1517 1.1564 1.1399 1.1751 
PTVspine     
    RBE98 1.1045 1.1044 1.1038 1.1043 
    RBE80 1.1478 1.1447 1.1427 1.1432 
    RBE50 1.2201 1.2119 1.2074 1.2081 
    RBE2 1.4906 1.4687 1.4489 1.4495 









    RBE98 1.1039 1.1041 1.1039 1.1041 
    RBE80 1.1412 1.1408 1.1404 1.1406 
    RBE50 1.2033 1.2020 1.2012 1.2014 
    RBE2 1.3840 1.3000 1.2986 1.2988 
    Mean 1.1667 1.1605 1.1511 1.1840 
Spinal Cord     
    RBE98 1.1040 1.1040 1.1040 1.1040 
    RBE80 1.1400 1.1400 1.1400 1.1400 
    RBE50 1.2000 1.2000 1.2000 1.2000 
    RBE2 1.2960 1.2960 1.2960 1.2960 
    Mean 1.1718 1.1703 1.1564 1.1861 
Stomach     
    RBE98 1.3809 1.3927 1.3090 1.3282 
    RBE80 1.6596 1.6756 1.5173 1.5590 
    RBE50 1.9452 1.9369 1.7533 1.7820 
    RBE2 7.0154 6.5407 6.1336 5.5287 
    Mean 2.4819 2.4219 2.2140 2.1647 
Thyroid     
    RBE98 1.3961 1.4668 1.3089 1.3173 
    RBE80 1.5687 1.5745 1.3961 1.4732 
    RBE50 1.6989 1.7022 1.5496 1.6037 
    RBE2 2.2554 2.1623 2.0330 1.9975 
    Mean 1.7481 1.7373 1.5806 1.6130 
Trachea     
    RBE98 1.3615 1.3365 1.3250 1.3210 
    RBE80 1.6538 1.5761 1.5256 1.5069 
    RBE50 1.9159 1.8342 1.7230 1.7011 
    RBE2 2.6755 2.5392 2.3769 2.2835 
    Mean 1.9504 1.8559 1.7558 1.7234 
 
Structures Uterus/Cervix and Vertebrae were not included due to very low doses (D2 < 0.5 






The following figures are additional patient slices. The slice used in section 5.2 is located at 
chest height. Figures D-1, D-3, D-5, D-7 and D-8 are of a patient slice slightly below shoulder 
height. Figure D-2, D-4, D-6 and D-9 are of a head slice at the eyes level. DVHs and data for 













Figure D-1: 2D patient dose distribution plots of the different models used in the thesis. The left column shows the 
different distributions and uses the color bar on the left. The right column shows the difference between the model 
distributions and the RBE1.1 (FLUKA) distribution showed in the top plot, while using the color bar on the right. The PTV 
is marked by the red curve, while other organs of interest such as the lungs (blue) and esophagus (green) are also marked. 
The dose values in the left column are transparent if the dose is less than 1 Gy. The axes in this figure are not shown, but 
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(g) MCNAMARA MODEL 
(c) WIL – RBE1.1 
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Figure D-2: 2D patient dose distribution plots of the different models used in the thesis. The left column shows the different distributions 
and uses the color bar on the left. The right column shows the difference between the model distributions and the FLUKA (RBE1.1) 
distribution showed in the top plot, while using the color bar on the right. The PTV is marked by the red curve, while other organs of 
interest such as the eyes (pink) are also marked. The dose values in the left column are transparent if the dose is less than 1 Gy. The axes 
in this figure are not shown, but are identical to that of figure 5-7. Unlike for the other dose distribution figures, the colorbar is between 
0 and 5. The head/brain was irradiated by two different fields, from roughly ±75 degrees of the depth axis as seen in (a).  The artifacts on 
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Figure D-3: Patient dose depth plot [Slice 2] 
 
Figure D-3: 1D depth equivalent to figure D-1 (shoulder). Depth = 0 cm refers to the point of entry into the 
patient, while approx. 9 cm is the point of exit. Note that the grey box which shows the boundary of the PTV on 
the depth-axis is the equivalent to the red curve in the 2D plot. 
 
Figure D-4: Patient dose depth plot [Slice 3] 
 
Figure D-4: 1D depth equivalent to figure D-2 (head). Depth = 0 cm refers to the back of the patient head, while 
approx. 18 cm is the front of the head. Note that the grey box which shows the boundary of the PTV on the 
depth-axis is the equivalent to the red curve in the 2D plot. The head/brain was irradiated by two different fields, 









   
  
   
Figure D-5: RBE distributions of the second slice of the patient. The top 4 plots (a-d) has a wide RBE range 
(1-3), while the bottom 4 (e-h) has a narrow RBE range (1-1.5). Marked structures are the PTV (red), lungs 
(blue) and esophagus (green). The dose values in the plots are transparent if the dose is less than 1 Gy. The 
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Figure D-6: RBE distribution of the third slice of the patient. Marked structures are the PTV (red) 
and eyes (pink). The axes in this figure are not shown, but are identical to that of figure 5-7. The 
head/brain was irradiated by two different fields, from roughly ±75 degrees of the depth axis as  
seen in (a). The artifacts on the top left and right are part of the apparatus holding the head in place. 
 
 
Figure D-7: Patient RBE depth plot [Slice 2] (wide RBE range) 
 
Figure D-7: 1D depth equivalent to figure D-5 (shoulder). Note that the grey box which shows the boundary of 
the PTV on the depth-axis is the equivalent to the red box in the 2D plot. Depth = 0 refers to the beam-entry 
point of the patient. 
(a) WIL 
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Figure D-8: Patient RBE depth plot [Slice 2] (narrow RBE range) 
 
Figure D-8: 1D depth equivalent to figure D-5 (shoulder), with a narrower RBE range. Note that the grey box 
which shows the boundary of the PTV on the depth-axis is the equivalent to the red box in the 2D plot. Depth = 0 
refers to the beam-entry point of the patient. 
 
Figure D-9: Patient RBE depth plot [Slice 3] 
 
Figure D-9: 1D depth equivalent to figure D-6 (head). Note that the grey box which shows the boundary of the 
PTV on the depth-axis is the equivalent to the red box in the 2D plot. Depth = 0 refers to the beam-entry point of 
the patient. The head/brain was irradiated by two different fields, from roughly ±75 degrees of the depth axis as 








Figure 5-1a and 5-1b show the two-dimensional dose distributions in the water phantom 
calculated by the TPS and FLUKA respectively. All the plots are normalized to the average 
dose in the PTV, on the assumption that the distribution calculated by FLUKA and the TPS are 
very similar in this region (Fjæra, 2016). From the comparison in figure 5-1c, it would appear 
that FLUKA scores lower in the center entrance region, while higher in the low-dose regions 
on the distribution. This is in accordance with the work of Fjæra (Fjæra, 2016). 
In the patient case with figure E-2, the FLUKA simulation seems to predict a higher dose in 
most areas, especially on the edges of the beam (like before) and in the center of the SOBP (like 
before). There is also dose distributed further past the PTV on the sides, which did not happen 
with the water phantom.  
 
Figure E-1: Water phantom dose distribution TPS vs FLUKA comparison 
Figure E-1: 2D water phantom dose distribution plots of the TPS (a) vs FLUKA (b). The bottom plot (c) shows 
the difference between the two, by subtracting the dose value in each voxel in the FLUKA matrix from the TPS 
matrix. The top plots use the color bar on the left, while the bottom plot uses the one on the right. The PTV is 
a 4x4x4 cm cube in the center of a 20x20x20 cm water phantom and the displayed slices are located in the 
center of the phantom and PTV. The dose values in the top plots are transparent if the dose is less than 0.5 Gy. 
(a) TPS (RBE1.1) (b) FLUKA (RBE1.1) 





Figure E-2: 2D patient dose distribution plots of the TPS (a) vs FLUKA (b). The bottom plot (c) shows the 
difference between the two, by subtracting the dose value in each voxel in the FLUKA matrix from the TPS 
matrix. The top plots use the color bar on the left, while the bottom plot uses the one on the right. The PTV is 
marked by the red curve, while other organs of interest such as the lungs (blue), heart (yellow) and esophagus 
(green) are also marked. Due to the way DICOM handles the axes, the center isn’t in 0,0 (x,y) as for the water 
phantom. Therefore, the displayed axes might seem confusing, but are displayed so that the 2D plots may be 
compared to the 1D plots and their axes. The dose values in the top plots are transparent if the dose is less 
than 1 Gy.  
Figure E-2: Patient [spinal] dose distribution TPS vs FLUKA comparison 
(a) TPS (RBE1.1) (b) FLUKA (RBE1.1) 
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